Cantel Medical (CMD) 10-Q 9 Jun 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Apr. 30, 2014	31-May-14
Document and Entity Information	'	'
Entity Registrant Name	'CANTEL MEDICAL CORP	'
Entity Central Index Key	'0000019446	'
Document Type	'10-Q	'
Document Period End Date	30-Apr-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--07-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	41,377,721
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Apr. 30, 2014	Jul. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$24,474,000	$34,076,000
Accounts receivable, net of allowance for doubtful accounts of $1,802 at April 30 and $1,265 at July 31	60,490,000	52,753,000
Inventories:	'	'
Raw materials	23,699,000	23,815,000
Work-in-process	7,125,000	6,945,000
Finished goods	25,668,000	23,407,000
Total inventories	56,492,000	54,167,000
Deferred income taxes	4,039,000	4,129,000
Prepaid expenses and other current assets	5,323,000	4,428,000
Income taxes receivable	1,213,000	1,107,000
Total current assets	152,031,000	150,660,000
Property and equipment, net	48,498,000	46,465,000
Intangible assets, net	73,981,000	75,929,000
Goodwill	218,857,000	211,618,000
Other assets	4,508,000	2,999,000
Total assets	497,875,000	487,671,000
Current liabilities:	'	'
Current portion of long-term debt	'	10,000,000
Accounts payable	15,768,000	13,322,000
Compensation payable	11,584,000	14,032,000
Accrued expenses	11,005,000	10,417,000
Deferred revenue	11,865,000	11,380,000
Total current liabilities	50,222,000	59,151,000
Long-term debt	64,500,000	85,000,000
Deferred income taxes	21,737,000	21,186,000
Contingent consideration	5,026,000	45,000
Other long-term liabilities	1,955,000	1,157,000
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued	'	'
Common Stock, par value $.10 per share; authorized 75,000,000 shares; April 30 - 45,565,440 shares issued and 41,379,053 shares outstanding; July 31 - 45,181,655 shares issued and 41,138,121 shares outstanding	4,557,000	4,518,000
Additional paid-in capital	143,600,000	134,853,000
Retained earnings	234,464,000	203,762,000
Accumulated other comprehensive income	9,569,000	10,977,000
Treasury Stock, at cost; April 30 - 4,186,387 shares; July 31 - 4,043,534 shares	-37,755,000	-32,978,000
Total stockholders' equity	354,435,000	321,132,000
Total liabilities and stockholders' equity	$497,875,000	$487,671,000

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Thousands, except Share data, unless otherwise specified
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$1,802	$1,265
Preferred Stock, par value (in dollars per share)	$1	$1
Preferred Stock, authorized shares	1,000,000	1,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value (in dollars per share)	$0.10	$0.10
Common Stock, authorized shares	75,000,000	75,000,000
Common Stock, shares issued	45,565,440	45,181,655
Common Stock, shares outstanding	41,379,053	41,138,121
Treasury Stock, shares	4,186,387	4,043,534

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF INCOME	'	'	'	'
Net sales	$120,058	$105,009	$357,372	$311,053
Cost of sales	67,640	59,525	201,120	176,691
Gross profit	52,418	45,484	156,252	134,362
Expenses:	'	'	'	'
Selling	16,532	15,096	48,373	42,232
General and administrative	16,428	13,766	47,149	38,196
Research and development	2,632	2,399	7,383	6,876
Total operating expenses	35,592	31,261	102,905	87,304
Income before interest and income taxes	16,826	14,223	53,347	47,058
Interest expense	552	749	1,854	2,186
Interest income	-17	-16	-45	-45
Income before income taxes	16,291	13,490	51,538	44,917
Income taxes	6,042	4,492	18,978	15,891
Net income	$10,249	$8,998	$32,560	$29,026
Earnings per common share:	'	'	'	'
Basic (in dollars per share)	$0.25	$0.22	$0.79	$0.71
Diluted (in dollars per share)	$0.25	$0.22	$0.79	$0.71
Dividends per common share (in dollars per share)	'	'	$0.05	$0.04

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	'	'	'	'
Net income	$10,249	$8,998	$32,560	$29,026
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation, net of tax	163	-192	-1,511	-37
Unrealized holding losses on interest rate swaps arising during the period, net of tax	'	-38	-30	-47
Reclassification adjustments to interest expense for losses on interest rate swap included in net income during the period, net of tax	'	31	60	105
Reclassification adjustments to interest expense for ineffective hedge on interest rate swap included in net income during the period, net of tax	'	'	73	'
Total other comprehensive income (loss), net of tax	163	-199	-1,408	21
Comprehensive income	$10,412	$8,799	$31,152	$29,047

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Cash flows from operating activities	'	'
Net income	$32,560,000	$29,026,000
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation	6,072,000	5,380,000
Amortization	7,882,000	7,438,000
Stock-based compensation expense	3,978,000	2,806,000
Amortization of debt issuance costs	340,000	262,000
Loss on disposal of fixed assets	302,000	124,000
Deferred income taxes	2,000	-99,000
Excess tax benefits from stock-based compensation	-3,815,000	-1,986,000
Changes in assets and liabilities, net of assets acquired and liabilities assumed:	'	'
Accounts receivable	-7,675,000	-2,136,000
Inventories	-2,080,000	-4,313,000
Prepaid expenses and other current assets	-1,353,000	-1,449,000
Accounts payable and other current liabilities	1,044,000	-3,848,000
Income taxes	3,470,000	3,286,000
Net cash provided by operating activities	40,727,000	34,491,000
Cash flows from investing activities	'	'
Capital expenditures	-7,886,000	-4,034,000
Proceeds from disposal of fixed assets	8,000	32,000
Acquisition of Jet Prep, net of cash acquired	-5,332,000	'
Acquisition of Sterilator, net of cash acquired	-2,829,000	'
Acquisition of SPS Business, net of cash acquired	'	-35,415,000
Acquisition of Polyp Trap	'	-486,000
Acquisition of Eagle Pure Water	'	-870,000
Acquisition of Siemens Water	'	-8,300,000
Other, net	-504,000	-135,000
Net cash used in investing activities	-16,543,000	-49,208,000
Cash flows from financing activities	'	'
Borrowings under revolving credit facility	'	45,000,000
Repayments under term loan facility	-5,000,000	-7,500,000
Repayments under revolving credit facility	-25,500,000	-22,500,000
Debt modification costs	-1,314,000	'
Proceeds from exercises of stock options	410,000	1,573,000
Dividends paid	-1,858,000	-1,494,000
Excess tax benefits from stock-based compensation	3,815,000	1,986,000
Purchases of treasury stock	-4,194,000	-1,899,000
Net cash (used in) provided by financing activities	-33,641,000	15,166,000
Effect of exchange rate changes on cash and cash equivalents	-145,000	34,000
(Decrease) increase in cash and cash equivalents	-9,602,000	483,000
Cash and cash equivalents at beginning of period	34,076,000	30,186,000
Cash and cash equivalents at end of period	$24,474,000	$30,669,000

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Apr. 30, 2014
Basis of Presentation	'
Basis of Presentation	'
	Note 1.                                 Basis of Presentation
	The unaudited Condensed Consolidated Financial Statements have been prepared in accordance with United States generally accepted accounting principles for interim financial reporting and the requirements of Form 10-Q and Rule 10.01 of Regulation S-X. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Annual Report of Cantel Medical Corp. (“Cantel”) on Form 10-K for the fiscal year ended July 31, 2013 (the “2013 Form 10-K”) and Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein.
	The unaudited interim financial statements reflect all adjustments (of a normal and recurring nature) which management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for the interim periods are not necessarily indicative of the results for the full year.
	The Condensed Consolidated Balance Sheet at July 31, 2013 was derived from the audited Consolidated Balance Sheet of Cantel at that date.
	Cantel had five principal operating companies at April 30, 2014 and July 31, 2013; Medivators Inc. (“Medivators”), Crosstex International, Inc. (“Crosstex”), Mar Cor Purification, Inc. (“Mar Cor”), Biolab Equipment Ltd. (“Biolab”) and Saf-T-Pak Inc. (“Saf-T-Pak”), all of which are wholly-owned operating subsidiaries. In addition, Medivators has two foreign subsidiaries, Medivators B.V. and Cantel Medical Asia/Pacific Pte. Ltd. (formerly known as Medivators Asia/Pacific Ltd.), which serve as our bases in Europe and Asia/Pacific, respectively, and Crosstex has a subsidiary, SPS Medical Supply Corp. (“SPS Medical”), as more fully described below and in Note 3 to the Condensed Consolidated Financial Statements.
	During the fourth quarter of fiscal 2013, we changed our internal reporting processes by combining our Therapeutic Filtration and Chemistries operating segments, previously reported in the Other reporting segment, with our Water Purification and Filtration reporting segment to reflect the way the Company, through its executive management, manages, allocates resources and measures the performance of its businesses. All periods presented have been recast to reflect these changes.
	As such, we currently operate our business through five operating segments: Endoscopy (through Medivators), Water Purification and Filtration (through Mar Cor, Biolab and Medivators), Healthcare Disposables (through Crosstex), Dialysis (through Medivators) and Specialty Packaging (through Saf-T-Pak). The Specialty Packaging operating segment comprises the Other reporting segment for financial reporting purposes.
	On January 7, 2014, we acquired all the issued and outstanding stock of Sterilator Company, Inc. (“Sterilator”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements (the “Sterilator Acquisition”). The Sterilator Acquisition had an insignificant effect on our consolidated results of operations for the three months ended April 30, 2014 and the portion of the nine months ended April 30, 2014 subsequent to its acquisition date due to the small size of this business (the “Sterilator Business”) and is not reflected in our consolidated results of operations for the three and nine months ended April 30, 2013. The Sterilator Business is included in our Healthcare Disposables segment.
	On November 5, 2013, we acquired all the issued and outstanding capital stock of Jet Prep Ltd. (“Jet Prep”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements (the “Jet Prep Acquisition”). The Jet Prep Acquisition did not have a significant effect on our consolidated results of operations for the three months ended April 30, 2014 and the portion of the nine months ended April 30, 2014 subsequent to its acquisition date due to the small size of this business (the “Jet Prep Business”) and is not reflected in our consolidated results of operations for the three and nine months ended April 30, 2013. The Jet Prep Business is included in our Endoscopy segment.
	On March 22, 2013, we entered into an agreement to acquire from Siemens Industry, Inc. and Siemens Canada Limited (collectively, “Siemens”) certain net assets of Siemens’ hemodialysis water business (the “Siemens Water Business”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements (the “Siemens Water Acquisition”). Due to the size of this business in relation to our overall consolidated results of operations, the Siemens Water Acquisition did not have a significant impact on our consolidated results of operations for the three and nine months ended April 30, 2014 and is not reflected in our consolidated results of operations for the three and nine months ended April 30, 2013. The Siemens Water Business is included in our Water Purification and Filtration segment.
	On December 31, 2012, we acquired certain net assets of Eagle Pure Water Systems, Inc. (“Eagle Pure Water”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements (the “Eagle Pure Water Acquisition”). The Eagle Pure Water Acquisition, which had an insignificant effect on our consolidated results of operations due to the small size of the business (the “Eagle Pure Water Business”), is reflected in our consolidated results of operations for the three and nine months ended April 30, 2014 and the portion of the three and nine months ended April 30, 2013 subsequent to its acquisition date. The Eagle Pure Water Business is included in our Water Purification and Filtration segment.
	On November 1, 2012, we acquired all the issued and outstanding stock of SPS Medical, as more fully described in Note 3 to the Condensed Consolidated Financial Statements (the “SPS Acquisition”). The results of operations of SPS Medical are included in our consolidated results of operations for the three and nine months ended April 30, 2014, the three months ended April 30, 2013, and the portion of the nine months ended April 30, 2013 subsequent to its acquisition date. The business of SPS Medical (the “SPS Business”) is included in our Healthcare Disposables segment.
	During July 2013, the Company issued 15,044,000 additional shares of common stock in connection with a three-for-two stock split effected in the form of a 50% stock dividend paid on July 12, 2013 to stockholders of record on July 1, 2013. The effect of the stock split has been recognized retroactively in all share data in the Condensed Consolidated Statements of Income, Notes to the Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations.
	Throughout this document, references to “Cantel,” “Cantel Medical,” “us,” “we,” “our,” and the “Company” are references to Cantel Medical Corp. and its subsidiaries, except where the context makes it clear the reference is to Cantel itself and not its subsidiaries.
	Subsequent Events
	On June 3, 2014, we agreed to acquire all the issued and outstanding capital stock of PuriCore International Limited (“Puricore”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements, (the “PuriCore Acquisition”). Since the PuriCore Acquisition is expected to be completed on or about June 30, 2014, its results of operations are not included in our results of operations for any periods presented.
	We performed a review of events subsequent to April 30, 2014. Based upon that review, no other subsequent events occurred that required updating to our Condensed Consolidated Financial Statements or disclosures.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Apr. 30, 2014
Stock-Based Compensation	'
Stock-Based Compensation	'
	Note 2.                                 Stock-Based Compensation
	The following table shows the income statement components of stock-based compensation expense recognized in the Condensed Consolidated Statements of Income:
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Cost of sales	$	109,000		$	41,000		$	280,000		$	133,000
	Operating expenses:
	Selling	190,000			69,000			491,000			250,000
	General and administrative	1,104,000			802,000			3,158,000			2,396,000
	Research and development	19,000			7,000			49,000			27,000
	Total operating expenses	1,313,000			878,000			3,698,000			2,673,000
	Stock-based compensation before income taxes	1,422,000			919,000			3,978,000			2,806,000
	Income tax benefits	(499,000		)	(332,000		)	(1,404,000		)	(1,008,000		)
	Total stock-based compensation expense, net of tax	$	923,000		$	587,000		$	2,574,000		$	1,798,000
	The above stock-based compensation expense before income taxes was recorded in the Condensed Consolidated Financial Statements as stock-based compensation expense and an increase to additional paid-in capital. The related income tax benefits were recorded as an increase to long-term deferred income tax assets (which are netted with long-term deferred income tax liabilities) and a reduction to income tax expense. All of our stock options and stock awards (which consist only of restricted shares) are expected to be deductible for tax purposes, except for certain options and restricted shares granted to employees residing outside of the United States, and were tax-effected using the Company’s estimated U.S. effective tax rate at the time of grant.
	All of our stock options and stock awards are subject to graded vesting in which portions of the award vest at different times during the vesting period, as opposed to awards that vest at the end of the vesting period. We recognize compensation expense for awards subject to graded vesting using the straight-line basis over the vesting period, reduced by estimated forfeitures. At April 30, 2014, total unrecognized stock-based compensation expense, before income taxes, related to total nonvested stock options and stock awards was $8,744,000 with a remaining weighted average period of 19 months over which such expense is expected to be recognized. Most of our nonvested awards relate to stock awards.
	We determine the fair value of each stock award using the closing market price of our common stock on the date of grant.
	A summary of nonvested stock award activity follows:
				Weighted
		Number of		Average
		Shares		Fair Value
	Nonvested stock awards at July 31, 2013	605,767		$	11.96
	Granted	247,136		31.84
	Canceled	(6,285	)	11.44
	Vested	(307,423	)	10.59
	Nonvested stock awards at April 30, 2014	539,195		$	21.86
	For the nine months ended April 30, 2014 and 2013, the Company granted 30,000 and 52,500 options, respectively.
	The fair value of each option grant was estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions for options granted during the nine months ended April 30, 2014 and 2013:
	Weighted-Average
	Black-Scholes Option	Nine Months Ended		Nine Months Ended
	Valuation Assumptions	April 30, 2014		April 30, 2013
	Dividend yield	0.28	%	0.37	%
	Expected volatility (1)	42.7	%	50.9	%
	Risk-free interest rate (2)	1.44	%	0.67	%
	Expected lives (in years) (3)	5		5
	(1) Volatility was based on historical closing prices of our common stock.
	(2) The U.S. Treasury rate on the expected life at the date of grant.
	(3) Based on historical exercise behavior.
	For the nine months ended April 30, 2014 and 2013, these non-qualified options had a weighted average fair value of $12.08 and $7.27, respectively.
	The aggregate intrinsic value (i.e., the excess market price over the exercise price) of all options exercised was $1,328,000 and $3,747,000 for the three and nine months ended April 30, 2014 and $537,000 and $4,025,000 for the three and nine months ended April 30, 2013, respectively.
	A summary of stock option activity follows:
				Weighted
		Number of		Average
		Shares		Exercise Price
	Outstanding at July 31, 2013	403,831		$	8.25
	Granted	30,000		31.81
	Exercised	(142,934	)	6.76
	Outstanding at April 30, 2014	290,897		$	11.41
	Exercisable at July 31, 2013	351,331		$	6.94
	Exercisable at April 30, 2014	225,897		$	7.83
	Upon exercise of stock options or grant of stock awards, we typically issue new shares of our common stock as opposed to using treasury shares. However, during the first six months of the nine months ended April 30, 2013, we reissued 474,266 shares from treasury stock for the exercise of stock options and grant of stock awards.
	If certain criteria are met when options are exercised or restricted stock becomes vested, the Company is allowed a deduction on its United States income tax return. Accordingly, we account for the income tax effect on such income tax deductions as a reduction of previously recorded long-term deferred income tax assets (which are netted with long-term deferred income tax liabilities) and as a reduction of income taxes payable in the year of the deduction. Excess tax benefits arise when the ultimate tax effect of the deduction for tax purposes is greater than the tax benefit on stock compensation expense which was determined based upon the award’s fair value at the time the award was granted. The differences noted above between actual tax deductions and the previously recorded long-term deferred income tax assets are recorded as additional paid-in capital. For the nine months ended April 30, 2014 and 2013, income tax deductions of $5,124,000 and $3,073,000, respectively, were generated and increased additional paid-in capital by $3,815,000 and $1,986,000, respectively. We classify the cash flows resulting from excess tax benefits as financing cash flows in our Condensed Consolidated Statements of Cash Flows.

Acquisitions

Acquisitions	9 Months Ended
	Apr. 30, 2014
Acquisitions	'
Acquisitions	'
	Note 3.                                 Acquisitions
	PuriCore International Limited
	On June 3, 2014, we entered into a definitive stock purchase agreement to acquire from PuriCore plc, a publicly traded company in the United Kingdom (“UK”), all the issued and outstanding stock of its subsidiary PuriCore, a company located in the UK with pre-acquisition annual revenues (unaudited) of approximately $25,000,000 that sells automated endoscope reprocessors and related equipment and consumables, as well as comprehensive maintenance and validation services, primarily in the UK market (the “PuriCore Business”). The transaction is anticipated to be completed on or about June 30, 2014. The total consideration for the transaction is $26,892,000, subject to adjustment and excluding transaction costs. The PuriCore Business will be included in our Endoscopy segment.
	The principal reasons for the acquisition are as follows: (i) the expansion of our product offerings with a broader range of advanced endoscope reprocessing equipment suitable for various international markets, (ii) the opportunity to sell our chemistries and other products to PuriCore’s installed base through a direct sales force, (iii) the ability to expand our footprint and infrastructure in Europe and (iv) the expectation that the acquisition will be accretive to our earnings per share in fiscal 2015 and beyond.
	Sterilator Company, Inc.
	On January 7, 2014, our Crosstex’ subsidiary acquired all the issued and outstanding stock of Sterilator, a private company based in Cuba, New York that manufactures biological indicators and supplies for sterility assurance products, which are used to accurately monitor the effectiveness of sterilization processes. The total consideration for the transaction was $2,829,000.
	The purchase price was preliminarily allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:
		Preliminary
	Net Assets	Allocation
	Current assets	$	538,000
	Property, plant and equipment	535,000
	Amortizable intangible assets (9- year weighted average life):
	Customer relationships (11- year life)	130,000
	Technology (8- year life)	510,000
	Current liabilities	(321,000		)
	Deferred income tax liabilities	(260,000		)
	Net assets acquired	$	1,132,000
	There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $1,697,000 was assigned to goodwill. Such goodwill, none of which is deductible for income tax purposes, has been included in our Healthcare Disposables segment.
	The principal reasons for this vertical acquisition were to (i) add one of our key long-standing suppliers of biological indicators to our portfolio providing a strategic benefit and cost savings to our overall sterility assurance monitoring business and (ii) strengthen our new product development and overall research and development capabilities. Such reasons constitute the significant factors that contributed to a purchase price that resulted in recognition of goodwill.
	The Sterilator Business is included in our results of operations for the three months ended April 30, 2014, the portion of the nine months ended April 30, 2014 subsequent to its acquisition date and is not reflected in the three and nine months ended April 30, 2013. This acquisition had an insignificant impact on our results of operations.
	Jet Prep Ltd.
	On November 5, 2013, our Medivators B.V. subsidiary acquired all the issued and outstanding capital stock of Jet Prep, a private Israeli company that developed the Jet PrepTM Endoscopic Flushing Device, a novel single-use irrigation and aspiration catheter to improve visualization during colonoscopy procedures. The device has FDA 510(k) and CE Mark clearances and is ready for commercialization by our global endoscopy sales force. Total consideration for the transaction, excluding transaction costs of $200,000, was $5,332,000 plus preliminarily estimated contingent consideration of $4,760,000 based on a percentage of sales above a minimum threshold over a seven year period, as further explained below. The Jet Prep Acquisition is included in our Endoscopy segment.
	We account for contingent consideration by recording the fair value of contingent consideration as a liability and an increase in goodwill on the date of the acquisition and continually re-measure the liability at each balance sheet date by recording changes in the fair value through our Condensed Consolidated Statements of Income. Accordingly, on November 5, 2013 we increased contingent consideration and goodwill by $4,760,000 to record our initial preliminary estimated fair value of the contingent consideration that would be earned over the seven year period ending November 4, 2020. On a quarterly basis subsequent to November 5, 2013, we re-measured the fair value of the contingent consideration and recorded the changes in fair value by increasing both contingent consideration and general administrative expenses, as further explained in Note 6 of the Condensed Consolidated Financial Statements. At April 30, 2014, the preliminary estimated fair value was $5,026,000 and was recorded in contingent consideration in the Condensed Consolidated Balance Sheets.
	In connection with the acquisition, we acquired certain ordinary course business assets and liabilities as well as an obligation to repay the Israeli Government for $810,000 of seed funding that was previously granted to Jet Prep. In accordance with the seed funding agreement, the Israeli Government is entitled to a return on their investment that can range from one to nine times their total grant based upon specific conditions set forth in the seed funding agreement and applicable Israeli law, including the acceleration of payments if we transfer certain operations of the company or intellectual property outside of Israel. We account for this assumed contingent obligation to the Israeli Government by recording the fair value as a liability and an increase in goodwill on the date of the acquisition and continually re-measure the liability at each balance sheet date by recording changes in the fair value through our Condensed Consolidated Statements of Income. Accordingly, on November 5, 2013 we increased accrued expenses by $58,000, other long-term liabilities by $932,000 and goodwill by $990,000 to record our initial estimated fair value of the assumed contingent obligation to the Israeli Government that would be earned on a percentage of sales over a forecasted period. On a quarterly basis subsequent to November 5, 2013, we re-measured the fair value of the assumed contingent liability and recorded the changes in fair value by increasing both other long-term liabilities and general administrative expenses, as further explained in Note 6 of the Condensed Consolidated Financial Statements. At April 30, 2014, the estimated fair value was $1,045,000, of which $58,000 was recorded in accrued expenses and $987,000 was recorded in other long-term liabilities.
	Since we will be continually re-measuring the contingent consideration liability and the assumed contingent obligation at each balance sheet date and recording changes in the respective fair values through our Condensed Consolidated Statements of Income, we may potentially have significant earnings volatility in our future results of operations until the completion of the seven year period with respect to the contingent consideration and until the assumed contingent obligation is satisfied or until sales of the Jet Prep Ltd. products no longer exist.
	The purchase price was preliminarily allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:
		Preliminary
	Net Assets	Allocation
	Current assets	$	64,000
	Property, plant and equipment	65,000
	Amortizable intangible asset:
	Technology (7- year life)	5,050,000
	Current liabilities	(158,000		)
	Deferred income tax liabilities	(345,000		)
	Other long-term liabilities	(932,000		)
	Net assets acquired	$	3,744,000
	There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $6,348,000 was assigned to goodwill. Such goodwill, none of which is deductible for income tax purposes, has been included in our Endoscopy segment.
	The principal reasons for the acquisition were (i) to address a market need for an effective technology that improves colonoscopy visualization through the use of irrigation and suction, (ii) to expand our endoscopy product portfolio further bolstering the Medivators brand in the gastrointestinal suite, (iii) to further expand our research and development capability by adding accomplished engineers to our existing research and development team and (iv) the expectation that the acquisition will be accretive to our earnings per share in fiscal 2015 and beyond.
	The Jet Prep Business is included in our results of operations for the three months ended April 30, 2014, the portion of the nine months ended April 30, 2014 subsequent to its acquisition date and is not reflected in the three and nine months ended April 30, 2013. Since we are only now beginning the commercialization of the Jet Prep Endoscopic Flushing Device, this acquisition has not yet generated any sales and did not have a significant impact on our results of operations.
	Siemens’ Hemodialysis Water Business
	On March 22, 2013, Mar Cor and Siemens entered into an asset purchase agreement under which Mar Cor acquired certain net assets of Siemens’ hemodialysis water business primarily consisting of customer service agreements for over 600 dialysis customers in the United States and Canada. Such service agreements had contributed over $9 million in revenue to Siemens in calendar year 2012 (unaudited) and were assigned from Siemens to Mar Cor on an individual customer by customer basis to ensure a seamless transition. The acquisition date of the Siemens Water Business was July 30, 2013, which is when the majority of the customer service agreements were transferred and therefore control of the business had been achieved. The total consideration for the transaction, excluding transaction costs of $362,000, was $8,300,000, which was paid on March 22, 2013.
	The purchase price was allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:
		Final
	Net Assets	Allocation
	Current assets	$	728,000
	Property, plant and equipment	231,000
	Amortizable intangible assets:
	Customer relationships (12- year life)	4,310,000
	Current liabilities	(415,000		)
	Net assets acquired	$	4,854,000
	There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $3,446,000 was assigned to goodwill. Such goodwill, all of which is deductible for income tax purposes, is included in our Water Purification and Filtration segment.
	The principal reasons for the acquisition were as follows: (i) the opportunity to increase service revenue and profitability of the Mar Cor service network due to improved operating leverage, (ii) the expansion of Mar Cor’s North American footprint into new geographies, (iii) the opportunity to sell capital equipment and recurring consumables to new customers and (iv) the expectation that the acquisition will be accretive to our earnings per share beyond fiscal 2013.
	Due to the size of this business in relation to our overall consolidated results of operations, the Siemens Water Acquisition did not have a significant effect on our results of operations for the three and nine months ended April 30, 2014 and is not reflected in our results of operations for the three and nine months ended April 30, 2013. The Siemens Water Business is included in our Water Purification and Filtration segment.
	Eagle Pure Water Systems, Inc.
	On December 31, 2012, Mar Cor purchased substantially all of the assets of Eagle Pure Water, a private company with pre-acquisition annual revenues (unaudited) of approximately $500,000 based outside of Philadelphia, Pennsylvania that provides water treatment services for laboratory, industrial and medical customers. The total consideration for the transaction was $870,000.
	The purchase price was allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:
		Final
	Net Assets	Allocation
	Current assets	$	8,000
	Property, plant and equipment	70,000
	Amortizable intangible assets (3- year weighted average life):
	Customer relationships (3- year life)	150,000
	Brand names (3- year life)	18,000
Non-compete agreement (5- year life)	32,000
Current liabilities	(5,000		)
Net assets acquired	$	273,000
There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $597,000 was assigned to goodwill. Such goodwill, all of which is deductible for income tax purposes, is included in our Water Purification and Filtration segment.
The principal reasons for the acquisition were the strengthening of our sales and service business by adding Eagle Pure Water’s strategic Philadelphia market presence to enable us to better serve our national customers and to further expand our business into the laboratory and research segments. Such reasons constitute the significant factors that contributed to a purchase price that resulted in recognition of goodwill.
The Eagle Pure Water Business is included in our results of operations for the three and nine months ended April 30, 2014, the three months ended April 30, 2013 and the portion of the nine months ended April 30, 2013 subsequent to its acquisition date. This acquisition had an insignificant impact on our results of operations.
Polyp Trap
On November 13, 2012, Medivators acquired the intellectual property, inventory, fixed assets and exclusive distribution rights of a polyp trap product line for $486,000.  This product line is used principally in the performance of endoscopy procedures for the purpose of safely and efficiently collecting tissue biopsy material.  The polyp trap product line is included in our Medivators procedural product portfolio, which is part of the Endoscopy segment.
This business is included in our results of operations for the three and nine months ended April 30, 2014, the three months ended April 30, 2013 and the portion of the nine months ended April 30, 2013 subsequent to its acquisition date. This acquisition had an insignificant impact on our results of operations.
SPS Medical Supply Corp.
On November 1, 2012, Crosstex acquired all the issued and outstanding stock of SPS Medical, a private company based in Rochester, New York with pre-acquisition annual revenues (unaudited) of approximately $17,500,000 that manufactures and provides biological and chemical indicators for sterility assurance monitoring services in the acute-care, alternate-care and dental markets. The SPS Business offers a wide-array of products and services that enable healthcare facilities to safely and accurately monitor and verify their sterilization practices and protocols. Total consideration for the transaction, excluding transaction costs of $157,000, was $32,500,000. In addition, we acquired SPS Medical’s manufacturing, warehouse and office facility in Rochester, New York for approximately $3,500,000 from an affiliate of SPS Medical. The SPS Business is included in our Healthcare Disposables segment.
The purchase price was allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:
	Final
Net Assets	Allocation
Current assets	$	4,810,000
Property, plant and equipment	3,801,000
Amortizable intangible assets (9- year weighted average life):
Customer relationships (10- year life)	8,120,000
Brand names (5- year life)	760,000
Technology (4- year life)	500,000
Non-compete agreements (6- year life)	180,000
Other assets	28,000
Current liabilities	(2,784,000		)
Noncurrent deferred income tax liabilities, net	(3,659,000		)
Net assets acquired	$	11,756,000
There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $24,244,000 was assigned to goodwill. Such goodwill, none of which is deductible for income tax purposes, has been included in our Healthcare Disposables segment.
The principal reasons for the acquisition were (i) to expand our sterility assurance monitoring product portfolio, (ii) to expand our market share of the dental mail-in biological monitoring industry when combined with our existing monitoring business, (iii) to expand into the acute-care hospital market and alternate care markets, (iv) to increase the likelihood of cross-selling our existing products, (v) to leverage Crosstex’ sales and marketing infrastructure and (vi) the expectation that the acquisition will be accretive to our earnings per share. Such reasons constitute the significant factors that contributed to a purchase price that resulted in recognition of goodwill.
The SPS Business is included in our results of operations for the three and nine months ended April 30, 2014, the three months ended April 30, 2013 and the portion of the nine months ended April 30, 2013 subsequent to its acquisition date.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Apr. 30, 2014
Recent Accounting Pronouncements	'
Recent Accounting Pronouncements	'
	Note 4.                                 Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2014-09”), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition.” ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. Since ASU 2014-09 was recently issued, we have not yet begun the process of evaluating the impact of ASU 2014-09 on our financial position and results of operations.
	In April 2014, the FASB issued ASU 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” (“ASU 2014-08”). Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on an organization’s operations and financial results. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. ASU 2014-08 is effective for fiscal years beginning after December 15, 2014, with early adoption allowed. We are currently in the process of evaluating the impact of ASU 2014-08 on our financial position and results of operations.
	In July 2013, the FASB issued ASU (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” (“ASU 2013-11”), which requires that a liability related to an unrecognized tax benefit be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of ASU 2013-11 is expected to have no impact on our financial condition, results of operations or cash flows.

Derivatives

Derivatives	9 Months Ended
	Apr. 30, 2014
Derivatives	'
Derivatives	'
	Note 5.                                 Derivatives
	We recognize all derivatives on the balance sheet at fair value. Derivatives that are not designated as hedges must be adjusted to fair value through earnings. If the derivative is designated as a hedge, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against the change in the fair value of the hedged assets, liabilities or firm commitments through earnings or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of the change in fair value of a derivative that is designated as a hedge will be recognized immediately in earnings. As of April 30, 2014, all of our derivatives were designated as hedges, except for our remaining interest rate swap agreement, as further explained below. We do not hold any derivative financial instruments for speculative or trading purposes.
	Changes in the value of (i) the Euro against the United States dollar, (ii) the Canadian dollar against the United States dollar, (iii) the Singapore dollar against the United States dollar and (iv) the British pound against the United States dollar affect our results of operations because certain cash bank accounts, accounts receivable, and liabilities of our subsidiaries are denominated and ultimately settled in United States dollars, Canadian dollars, Euros, Singapore dollars or British pounds, but must be converted into their functional currency.
	In order to hedge against the impact of fluctuations in the value of (i) the Euro relative to the United States dollar, (ii) the Singapore dollar relative to the United States dollar and (iii) the British pound relative to the United States dollar on the conversion of such net assets into the functional currencies, we enter into short-term contracts to purchase Euros, Singapore dollars and British pounds forward, which contracts are one month in duration. These short-term contracts are designated as fair value hedge instruments. There were three foreign currency forward contracts with an aggregate value of $11,874,000 at April 30, 2014, which covered certain assets and liabilities that were denominated in currencies other than our subsidiaries’ functional currencies. Such contracts expired on May 31, 2014. These foreign currency forward contracts are continually replaced with new one-month contracts as long as we have significant net assets at our subsidiaries that are denominated and ultimately settled in currencies other than their functional currencies. Such forward contracts substantially offset the impact on operations relating to certain assets and liabilities that were denominated in currencies other than our subsidiaries’ functional currencies resulting in a net currency conversion gain, net of tax, of $26,000 for the three months ended April 30, 2014 and a net currency conversion loss, net of tax, of $70,000 for the nine months ended April 30, 2014 on the items hedged. For the three and nine months ended April 30, 2013, such forward contracts substantially offset the impact on operations relating to certain assets and liabilities that were denominated in currencies other than our subsidiaries’ functional currencies resulting in a net currency conversion loss, net of tax, of $2,000 and $46,000, respectively, on the items hedged.  Gains and losses related to hedging contracts to buy Euros, Singapore dollars and British pounds forward are immediately realized within general and administrative expenses due to the short-term nature of such contracts. We do not currently hedge against the impact of fluctuations in the value of the Canadian dollar relative to the United States dollar because the currency impact on our Canadian and United States subsidiaries’ assets closely offset the currency impact on our Canadian and United States subsidiaries’ liabilities effectively minimizing realized gains and losses.
	The interest rate on our outstanding borrowings under our credit facilities is variable and is affected by the general level of interest rates in the United States as well as LIBOR interest rates, as more fully described in Note 9 to the Condensed Consolidated Financial Statements. In order to protect our interest rate exposure in future years, we entered into forward starting interest rate swap agreements in February 2012 in which we agree to exchange our variable interest cash flows with fixed interest cash flows provided by one of our existing senior lenders. Such interest rate swap agreements were designated as cash flow hedge instruments and were designed to be effective in offsetting changes in the cash flows related to the hedged borrowings. With respect to our former term loan facility, the interest rate swap is for the period that began August 8, 2012 and ends July 31, 2015, initially covering $40,000,000 of borrowings based on one-month LIBOR and thereafter reducing in quarterly $2,500,000 increments consistent with the mandatory repayment schedule, and the fixed interest cash flow is at a one month LIBOR rate of 0.664%. With respect to our revolving credit facility, the interest rate swap was for the period that began August 8, 2012 and ended January 31, 2014, initially covering $25,000,000 of borrowings based on one-month LIBOR and thereafter reduced semi-annually by increments of $5,000,000, and the fixed interest cash flow was at a one month LIBOR rate of 0.496%. As more fully described in Note 6 to the Condensed Consolidated Financial Statements, we account for the interest rate swap agreements by initially recording the fair value of the derivative instrument on the balance sheet as either an asset or liability, with a corresponding amount recorded in accumulated other comprehensive income. Amounts are reclassified from accumulated other comprehensive income to interest expense in the Condensed Consolidated Statements of Income in the period the hedged transaction affects earnings. At the hedge’s inception and on a regular basis thereafter, a formal assessment is performed to determine whether changes in the fair value or cash flows of the derivative instruments have been highly effective in offsetting changes in cash flows of the hedged items and whether they are expected to be highly effective in the future. This formal assessment includes a comparison of the terms of the interest rate swap agreements and hedged borrowings to ensure they coincide as well as an evaluation of the continued ability of the counterparty to the interest rate swap agreements and the Company to honor their obligations under such agreements. At January 31, 2014, our formal assessment concluded that the changes in the fair value of both derivative instruments that began on August 8, 2012 had been highly effective. However, the remaining derivative instrument at April 30, 2014, which relates solely to our former term loan facility, was determined to be ineffective beginning as of January 31, 2014 due to the modifications to our credit facilities in March 2014, as more fully described in Note 9 to the Condensed Consolidated Financial Statements. Accordingly, the fair value of the interest rate swap agreement of $113,000 relating to our former term loan facility was recognized in interest expense in January 2014. Changes in the fair value of the derivative instrument subsequent to January 31, 2014 are recognized immediately in interest expense.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Apr. 30, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	Note 6.                                 Fair Value Measurements
	Fair Value Hierarchy
	We apply the provisions of Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. We define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three level fair value hierarchy to prioritize the inputs used in valuations, as defined below:
	Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.
	Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
	Level 3: Unobservable inputs for the asset or liability.
	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis
	As of April 30, 2014 and 2013, our financial assets that are re-measured at fair value on a recurring basis include money market funds that are classified as cash and cash equivalents in the Condensed Consolidated Balance Sheets. As there are no withdrawal restrictions, they are classified within Level 1 of the fair value hierarchy and are valued using quoted market prices for identical assets.
	In order to protect our interest rate exposure in future years, we entered into forward starting interest rate swap agreements in February 2012 in which we agreed to exchange our variable interest cash flows with fixed interest cash flows provided by one of our existing senior lenders, as further described in Notes 5 and 9 to the Condensed Consolidated Financial Statements. Our interest rate swap agreements are classified within Level 2 and are valued using discounted cash flow analyses based on the terms of the contracts and interest rate curves. Changes in fair value in the interest rate swap agreement relating to our revolving credit facility during the six months ended January 31, 2014 and 2013 were recorded in accumulated other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income. Amounts were reclassified from accumulated other comprehensive income in the period the hedged transaction affected earnings. Similarly, changes in fair value in the interest rate swap agreement relating to our former term loan facility were recorded in accumulated other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income until January 31, 2014, at which time the interest rate swap agreement was determined to be ineffective and the remaining fair value of the derivative instrument was recognized in interest expense, as further explained in Note 5 to the Condensed Consolidated Financial Statements.
	On November 5, 2013, we recorded a $4,760,000 liability for the estimated fair value of contingent consideration and a $990,000 liability for the estimated fair value of an assumed contingent obligation payable to the Israeli Government relating to the Jet Prep Acquisition, as further described in Note 3 to the Condensed Consolidated Financial Statements. These fair value measurements were based on significant inputs not observed in the market and thus represent Level 3 measurements.
	The fair values of the contingent consideration liability and assumed contingent obligation were based on percentages of future sales projections of the Jet Prep Business, above a minimum threshold with respect to the contingent consideration, under various potential scenarios over a seven year period ending November 4, 2020 and weighting the probability of these outcomes.  As such, the determinations of fair values of these contingent liabilities are subjective in nature and highly dependent on future sales projections.  At the date of the acquisition, the cash flow projections relating to the contingent consideration and assumed contingent obligation were discounted using a rate of 11.5%. The discount rate was based on the weighted average cost of capital of the acquired business plus a credit risk premium for non-performance risk. These two liabilities will be adjusted periodically by recording changes in the fair value through our Condensed Consolidated Statements of Income driven by the time value of money and changes in the assumptions that were initially used in the valuations. Due to the structure of the acquisition, any such adjustments through our Condensed Consolidated Statements of Income will not be tax effected, except for amounts in excess of $810,000 with respect to the assumed contingent obligation, therefore impacting our effective tax rate.
	The actual contingent consideration and assumed contingent obligation have the potential of being between zero and a percentage of unlimited sales that could occur until the completion of the seven year period with respect to the contingent consideration liability and until the assumed contingent obligation is satisfied in full, or until the sales of the Jet Prep Ltd. products no longer exist. However, with respect to the contingent consideration, the different likely scenarios of future sales projections used in our fair value determination resulted in total potential contingent consideration payments ranging between zero and approximately $12,000,000 and the weighted average present value of such scenarios plus the accretion of interest for the passing of time resulted in a fair value of $5,026,000 at April 30, 2014. With respect to the assumed contingent obligation, the different likely scenarios of future sales projections used in our fair value determination resulted in total potential future payments ranging between zero and approximately $2,430,000 and the weighted average present value of such scenarios plus the accretion of interest for the passing of time resulted in a fair value of $1,045,000 at April 30, 2014. Such fair value amounts would have been higher or lower if we had used different probability factors, future sales projections or discount factors. Given the subjective nature of the assumptions used in the determinations of fair value, we may potentially have significant earnings volatility in our future results of operations.
	On August 1, 2011 (the first day of our fiscal 2012), we recorded a $2,700,000 liability for the estimated fair value of contingent consideration and a $3,000,000 liability for the estimated fair value of a three year price floor relating to the August 1, 2011 acquisition of the endoscopy procedural product business of Byrne Medical, Inc. (the “Byrne Medical Business” or the “Byrne Acquisition”). These fair value measurements were based on significant inputs not observed in the market and thus represent Level 3 measurements.
	The fair value of the contingent consideration liability was based on future gross profit projections of the Byrne Medical Business under various potential scenarios for the two year period ended July 31, 2013 and weighting the probability of these outcomes. As such, the determination of fair value of the contingent consideration is subjective in nature and highly dependent on future gross profit projections.  At the date of the acquisition, these cash flow projections were discounted using a rate of 14%. The discount rate was based on the weighted average cost of capital of the acquired business plus a credit risk premium for non-performance risk. This contingent consideration liability was adjusted periodically by recording changes in the fair value through our Condensed Consolidated Statements of Income. Based on actual gross profit results for the two year period ended July 31, 2013, contingent consideration was not earned.
	After giving effect for the Company’s three-for-two stock splits, the stock portion of the consideration paid for the Byrne Acquisition consisted of 902,528 shares of Cantel common stock and was based on the closing price of Cantel common stock on the NYSE on July 29, 2011 ($11.08). Subject to certain conditions and limitations, under a three year price floor, we agreed that if the aggregate value of the stock consideration is less than $10,000,000 on July 31, 2014, we will pay to the sellers in cash or stock (at our option) an amount equal to the difference between $10,000,000 and the then value of the shares (based on the closing price of Cantel common stock on the NYSE on July 31, 2014). This three-year price floor is a free standing financial instrument that we recorded as a liability at fair value on the date of acquisition. The 902,528 shares of Cantel common stock were (i) placed in escrow at the time of the acquisition as security for certain indemnification obligations of the sellers and (ii) subjected to a multi-year lock-up feature prohibiting the sellers from selling or otherwise transferring the shares. In November 2013, one-third of the shares were released from escrow and the lock-up feature. Likewise, the three year price floor was modified to exclude the released shares and reduce the $10,000,000 value guaranty by one-third to $6,666,666.
	The fair value of the three year price floor liability was determined using the Black-Scholes option valuation model, which is affected by our stock price and risk free interest rate as well as assumptions regarding a number of subjective variables, including, but not limited to, the expected stock price volatility of our common stock over the expected life of the instrument and the expected dividend yield. This liability is adjusted periodically by recording changes in the fair value through our Condensed Consolidated Statements of Income, as shown below in the reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis, driven by the time value of money and changes in the assumptions that were initially used in the valuation. The decrease to the fair value of the price floor (as determined by the Black-Scholes option valuation model) was recorded as a decrease to accrued expenses or contingent consideration and general and administrative expenses in the Condensed Consolidated Financial Statements and was primarily due to the impact of our stock price being higher than at the time of the acquisition, the life of the price floor being less than three years and changes in the expected stock price volatility.
	The fair values of the Company’s financial instruments measured on a recurring basis were categorized as follows:
		April 30, 2014
		Level 1			Level 2			Level 3		Total
	Assets:
	Cash and cash equivalents:
	Money markets	$	1,533,000		$	—		$	—	$	1,533,000
	Total assets	$	1,533,000		$	—		$	—	$	1,533,000
	Liabilities:
	Accrued expenses:
	Assumed contingent obligation	$	—		$	—		$	58,000	$	58,000
	Interest rate swap agreement	—			88,000			—		88,000
	Total accrued expenses	—			88,000			58,000		146,000
	Contingent consideration	—			—			5,026,000		5,026,000
	Other long-term liabilities:
	Assumed contingent obligation	—			—			987,000		987,000
	Interest rate swap agreement	—			9,000			—		9,000
	Total other long-term liabilities	—			9,000			987,000		996,000
	Total liabilities	$	—		$	97,000		$	6,071,000	$	6,168,000
		July 31, 2013
		Level 1			Level 2			Level 3		Total
	Assets:
	Cash and cash equivalents:
	Money markets	$	4,241,000		$	—		$	—	$	4,241,000
	Total assets	$	4,241,000		$	—		$	—	$	4,241,000
	Liabilities:
	Accrued expenses:
	Interest rate swap agreements	$	—		$	133,000		$	—	$	133,000
	Total accrued expenses	—			133,000			—		133,000
	Contingent consideration	—			—			45,000		45,000
	Other long-term liabilities:
	Interest rate swap agreements	—			29,000			—		29,000
	Total liabilities	$	—		$	162,000		$	45,000	$	207,000
	A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) for the last seven quarters is as follows:
										Jet Prep
		Byrne			Byrne			Jet Prep		Assumed
		Contingent			Price			Contingent		Contingent
		Consideration			Floor			Consideration		Obligation		Total
	Balance, July 31, 2012	$	1,500,000		$	1,037,000		$	—	$	—	$	2,537,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(313,000		)	—		—		(313,000		)
	Balance, October 31, 2012	1,500,000			724,000			—		—		2,224,000
	Total net unrealized gains included in general and administrative expense in earnings	(1,500,000		)	(410,000		)	—		—		(1,910,000		)
	Balance, January 31, 2013	—			314,000			—		—		314,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(59,000		)	—		—		(59,000		)
	Balance, April 30, 2013	—			255,000			—		—		255,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(210,000		)	—		—		(210,000		)
	Balance, July 31, 2013	—			45,000			—		—		45,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(44,000		)	—		—		(44,000		)
Balance, October 31, 2013	—			1,000			—		—		1,000
Total net unrealized gains included in general and administrative expense in earnings	—			(1,000		)	—		—		(1,000		)
Net purchases, issuances, sales and settlements	—			—			4,760,000		990,000		5,750,000
Balance, January 31, 2014	—			—			4,760,000		990,000		5,750,000
Total net unrealized losses included in general and administrative expense in earnings	—			—			266,000		55,000		321,000
Balance, April 30, 2014	$	—		$	—		$	5,026,000	$	1,045,000	$	6,071,000
Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
We re-measure the fair value of certain assets, such as intangible assets, goodwill and long-lived assets, including property, equipment and other assets, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, and goodwill and intangible assets with indefinite lives are reviewed for impairment at least annually. In performing a review for goodwill impairment, management first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount before proceeding to step one of the two-step quantitative goodwill impairment test, if necessary. For our quantitative test, we use a two-step process that begins with an estimation of the fair value of the related operating segments by using fair value results of the discounted cash flow methodology, as well as the market multiple and comparable transaction methodologies. The first step is a review for potential impairment, and the second step measures the amount of impairment, if any. In performing our annual review for indefinite lived intangibles, management performs a qualitative assessment, and if a quantitative assessment is necessary, we compare the current fair value of such assets to their carrying values. With respect to amortizable intangible assets when impairment indicators are present, management determines whether expected future non-discounted cash flows are sufficient to recover the carrying value of the assets; if not, the carrying value of the assets is adjusted to their fair value. With respect to long-lived assets, an assessment is made to determine if the sum of the expected future non-discounted cash flows from the use of the assets and eventual disposition is less than the carrying value. If the sum of the expected non-discounted cash flows is less than the carrying value, an impairment loss is recognized based on fair value. As the inputs utilized for our periodic impairment assessments are not based on observable market data, but are based on management’s assumptions and estimates, our goodwill, intangibles and long-lived assets are classified within Level 3 of the fair value hierarchy on a non-recurring basis. On July 31, 2013, management concluded that none of our long-lived assets, including goodwill and intangibles with indefinite-lives, were impaired and no other events or changes in circumstances have occurred during the nine months ended April 30, 2014 that would indicate that the carrying amount of our long-lived assets may not be recoverable.
Disclosure of Fair Value of Financial Instruments
As of April 30, 2014 and July 31, 2013, the carrying amounts for cash and cash equivalents (excluding money markets), accounts receivable and accounts payable approximated fair value due to the short maturity of these instruments. We believe that as of April 30, 2014 and July 31, 2013, the fair value of our outstanding borrowings under our credit facility approximated the carrying value of those obligations since the borrowing rates were at prevailing market interest rates, principally under LIBOR contracts ranging from one to twelve months.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Apr. 30, 2014
Intangible Assets and Goodwill	'
Intangible Assets and Goodwill	'
	Note 7.                                 Intangible Assets and Goodwill
	Our intangible assets with definite lives consist of customer relationships, technology, brand names, non-compete agreements and patents. These intangible assets are being amortized using the straight-line method over the estimated useful lives of the assets ranging from 2-20 years and have a weighted average amortization period of 11 years. Amortization expense related to definite lived intangible assets was $2,637,000 and $7,882,000 for the three and nine months ended April 30, 2014, respectively, and $2,598,000 and $7,438,000 for the three and nine months ended April 30, 2013, respectively. Our intangible assets that have indefinite useful lives, and therefore are not amortized, consist of trademarks and trade names.
	The Company’s intangible assets consist of the following:
		April 30, 2014
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	71,955,000	$	(29,655,000	)	$	42,300,000
	Technology	25,980,000		(10,820,000		)	15,160,000
	Brand names	12,680,000		(9,085,000		)	3,595,000
	Non-compete agreements	3,129,000		(693,000		)	2,436,000
	Patents and other registrations	1,973,000		(750,000		)	1,223,000
		115,717,000		(51,003,000		)	64,714,000
	Trademarks and trade names	9,267,000		—			9,267,000
	Total intangible assets	$	124,984,000	$	(51,003,000	)	$	73,981,000
		July 31, 2013
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	72,142,000	$	(25,379,000	)	$	46,763,000
	Technology	21,006,000		(9,642,000		)	11,364,000
	Brand names	12,680,000		(8,045,000		)	4,635,000
	Non-compete agreements	3,159,000		(541,000		)	2,618,000
	Patents and other registrations	1,768,000		(606,000		)	1,162,000
		110,755,000		(44,213,000		)	66,542,000
	Trademarks and trade names	9,387,000		—			9,387,000
	Total intangible assets	$	120,142,000	$	(44,213,000	)	$	75,929,000
	Estimated amortization expense of our intangible assets for the remainder of fiscal 2014 and the next five years is as follows:
	Three month period ending July 31, 2014	$	2,879,000
	Fiscal 2015	11,032,000
	Fiscal 2016	7,793,000
	Fiscal 2017	7,217,000
	Fiscal 2018	6,940,000
	Fiscal 2019	6,617,000
	Goodwill changed during fiscal 2013 and the nine months ended April 30, 2014 as follows:
				Water
				Purification			Healthcare							Total
		Endoscopy		and Filtration			Disposables		Dialysis		Other			Goodwill
	Balance, July 31, 2012	$	59,230,000	$	53,288,000		$	55,864,000	$	8,133,000	$	7,140,000		$	183,655,000
	Acquisitions	—		4,043,000			24,244,000		—		—			28,287,000
	Foreign currency translation	—		(152,000		)	—		—		(172,000		)	(324,000		)
	Balance, July 31, 2013	59,230,000		57,179,000			80,108,000		8,133,000		6,968,000			211,618,000
	Acquisitions	6,348,000		—			1,697,000		—		—			8,045,000
	Foreign currency translation	—		(370,000		)	—		—		(436,000		)	(806,000		)
	Balance, April 30, 2014	$	65,578,000	$	56,809,000		$	81,805,000	$	8,133,000	$	6,532,000		$	218,857,000
	On July 31, 2013, we performed impairment studies of the Company’s goodwill and indefinite lived trademarks and trade names and concluded that such assets were not impaired. While the results of these annual reviews have historically not indicated impairment, impairment reviews are highly dependent on management’s projections of our future operating results and cash flows (which management believes to be reasonable), discount rates based on the Company’s weighted average cost of capital and appropriate benchmark peer companies. Assumptions used in determining future operating results and cash flows include current and expected market conditions and future sales forecasts. Subsequent changes in these assumptions and estimates could result in future impairment. Although we consistently use the same methods in developing the assumptions and estimates underlying the fair value calculations, such estimates are uncertain by nature and can vary from actual results. At July 31, 2013, the average fair value of all of our reporting units exceeded book value by substantial amounts, except our Specialty Packaging segment, which had an average estimated fair value that approximated book value. At April 30, 2014, goodwill relating to our Specialty Packaging reporting unit was $6,532,000. We believe the most significant assumptions impacting the impairment assessment of Specialty Packaging relate to the assumed compounded annual sales growth and future operating efficiencies included in our projections of future operating results and cash flows of this segment, which projections are in excess of historical run rates. If future operating results and cash flows are substantially less than our projections, future impairment charges may be recorded. On April 30, 2014, management concluded that no events or changes in circumstances have occurred during the three and nine months ended April 30, 2014 that would indicate that the carrying amount of our intangible assets and goodwill may not be recoverable.

Warranties

Warranties	9 Months Ended
	Apr. 30, 2014
Warranties	'
Warranties	'
	Note 8.                                 Warranties
	A summary of activity in the Company’s warranty reserves follows:
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Beginning balance	$	1,201,000		$	1,232,000		$	1,261,000		$	1,667,000
	Provisions	583,000			479,000			1,820,000			1,182,000
	Settlements	(567,000		)	(634,000		)	(1,863,000		)	(1,772,000		)
	Foreign currency translation	—			—			(1,000		)	—
	Ending balance	$	1,217,000		$	1,077,000		$	1,217,000		$	1,077,000
	The warranty provisions and settlements for the three and nine months ended April 30, 2014 and 2013 relate principally to the Company’s endoscope reprocessing and water purification equipment. Warranty reserves are included in accrued expenses in the Condensed Consolidated Balance Sheets.

Financing_Arrangements

Financing Arrangements	9 Months Ended
	Apr. 30, 2014
Financing Arrangements	'
Financing Arrangements	'
	Note 9.                                 Financing Arrangements
	In March 2014, we modified our existing $100,000,000 senior secured revolving credit facility (the “Existing Revolving Credit Facility”) and $50,000,000 senior secured term loan facility (the “Existing Term Loan Facility”) by entering into a $250,000,000 Third Amended and Restated Credit Agreement dated as of March 4, 2014 (the “New Credit Agreement”). The New Credit Agreement includes a five-year $250,000,000 senior secured revolving facility with sublimits of up to $100,000,000 for borrowings in foreign currencies, $30,000,000 for letters of credit and $10,000,000 for swing line loans (the “New Revolving Credit Facility”).  The Existing Term Loan Facility was terminated after the outstanding balance was reassigned to the New Revolving Credit Facility. Subject to the satisfaction of certain conditions precedent including the consent of the lenders, the Company may from time to time increase the New Revolving Credit Facility by an aggregate amount not to exceed $100,000,000. The senior lenders include Bank of America N.A. (the lead bank and administrative agent), PNC Bank, National Association, and Wells Fargo Bank, National Association. The New Credit Agreement expires on March 4, 2019. Additionally, subject to certain restrictions and conditions (i) any of Cantel’s domestic or foreign subsidiaries may become borrowers and (ii) borrowings may occur in multi-currencies. Furthermore, we incurred debt issuance costs of $1,318,000 relating to the New Credit Agreement which was recorded in other assets along with the remaining unamortized debt issuance costs of $512,000 relating to the Existing Revolving Credit Facility. The total of these two amounts are being amortized over the life of the New Credit Agreement. The remaining unamortized debt issuance costs of $84,000 relating to the Existing Term Loan Facility was charged to interest expense on March 4, 2014 when the Existing Term Loan Facility was terminated. At April 30, 2014, unamortized debt issuance costs recorded in other assets amounted to $1,769,000.
	Borrowings under the New Credit Agreement bear interest at rates ranging from 0.25% to 1.25% above the lender’s base rate, or at rates ranging from 1.25% to 2.25% above the London Interbank Offered Rate (“LIBOR”), depending upon the Company’s “Consolidated Leverage Ratio,” which is defined as the consolidated ratio of total funded debt to earnings before interest, taxes, depreciation and amortization, and as further adjusted under the terms of the New Credit Agreement (“Consolidated EBITDA”). At April 30, 2014, the lender’s base rate was 3.50% and the LIBOR rates ranged from 0.33% to 0.70%. The margins applicable to our outstanding borrowings were 0.25% above the lender’s base rate or 1.25% above LIBOR. Substantially all of our outstanding borrowings were under LIBOR contracts at April 30, 2014. The New Credit Agreement also provides for fees on the unused portion of our facilities at rates ranging from 0.20% to 0.40%, depending upon our Consolidated Leverage Ratio; such rate was 0.20% at April 30, 2014.
	In order to protect our interest rate exposure in future years, we entered into forward starting interest rate swap agreements in February 2012 in which we agreed to exchange our variable interest cash flows with fixed interest cash flows provided by one of our existing senior lenders. With respect to our Existing Term Loan Facility, the interest rate swap is for the period that began August 8, 2012 and ends July 31, 2015, initially covering $40,000,000 of borrowings based on one-month LIBOR and thereafter reducing in quarterly $2,500,000 increments consistent with the mandatory repayment schedule, and the fixed interest cash flow is at a one month LIBOR rate of 0.664%. As a result of the termination of our Existing Term Loan Facility, this interest rate swap is no longer considered effective in mitigating the adverse impact on interest expense of increases in LIBOR. With respect to our Existing Revolving Credit Facility, the interest rate swap was for the period that began August 8, 2012 and ended January 31, 2014, initially covering $25,000,000 of borrowings based on one-month LIBOR and thereafter reducing semi-annually by increments of $5,000,000, and the fixed interest cash flow was at a one month LIBOR rate of 0.496%.
	The New Credit Agreement contains affirmative and negative covenants reasonably customary for similar credit facilities and is secured by (i) substantially all assets of Cantel and its United States-based subsidiaries, (ii) a pledge by Cantel of all of the outstanding shares of its United States-based subsidiaries and 65% of the outstanding shares of certain of Cantel’s foreign-based subsidiaries and (iii) a guaranty by Cantel’s domestic subsidiaries. We are in compliance with all financial and other covenants under the New Credit Agreement.
	On April 30, 2014, we had $64,500,000 of outstanding borrowings under the New Revolving Credit Facility.  Subsequent to April 30, 2014, we repaid $9,500,000 resulting in total outstanding borrowings of $55,000,000 at June 9, 2014, none of which is required to be repaid until March 2019.

Earnings_Per_Common_Share

Earnings Per Common Share	9 Months Ended
	Apr. 30, 2014
Earnings Per Common Share	'
Earnings Per Common Share	'
	Note 10.                          Earnings Per Common Share
	Basic EPS is computed based upon the weighted average number of common shares outstanding during the period. Diluted EPS is computed based upon the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.
	We include participating securities (unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents) in the computation of EPS pursuant to the two-class method. Our participating securities consist solely of unvested restricted stock awards, which have contractual participation rights equivalent to those of stockholders of unrestricted common stock. The two-class method of computing earnings per share is an allocation method that calculates earnings per share for common stock and participating securities.
	The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities):
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Numerator for basic and diluted earnings per share:
	Net income	$	10,249,000		$	8,998,000		$	32,560,000		$	29,026,000
	Less income allocated to participating securities	(135,000		)	(137,000		)	(444,000		)	(454,000		)
	Net income available to common stockholders	$	10,114,000		$	8,861,000		$	32,116,000		$	28,572,000
	Denominator for basic and diluted earnings per share, as adjusted for participating securities:
	Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	40,813,778			40,365,939			40,716,018			40,201,691
	Dilutive effect of stock options using the treasury stock method and the average market price for the period	143,319			258,719			174,107			315,692
	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,957,097			40,624,658			40,890,125			40,517,383
	Earnings per share attributable to common stock:
	Basic earnings per share	$	0.25		$	0.22		$	0.79		$	0.71
	Diluted earnings per share	$	0.25		$	0.22		$	0.79		$	0.71
	Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive	30,000			—			—			—
	A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to the Company’s total weighted average number of shares and common stock equivalents, including participating securities, are set forth in the following table:
		Three Months Ended				Nine Months Ended
		April 30,				April 30,
		2014		2013		2014		2013
	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,957,097		40,624,658		40,890,125		40,517,383
	Participating securities	544,752		626,415		566,545		646,104
	Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,501,849		41,251,073		41,456,670		41,163,487

Income_Taxes

Income Taxes	9 Months Ended
	Apr. 30, 2014
Income Taxes	'
Income Taxes	'
	Note 11.                          Income Taxes
	The consolidated effective tax rate was 36.8% and 35.4% for the nine months ended April 30, 2014 and 2013, respectively. The increase in the consolidated effective tax rate was principally due to the geographic mix of pre-tax income and the impact of Federal tax legislation re-enacted in January 2013 but subsequently expired in December 2013, as described below.
	For the nine months ended April 30, 2014 and 2013, approximately 97% and 96%, respectively, of our income before income taxes was generated from our United States operations, which had an overall effective tax rate of 37.4% and 36.4%, respectively. The higher overall effective tax rate for the nine months ended April 30, 2014 was principally caused by Federal tax legislation that had expired in December 2011, but was re-enacted retroactively in January 2013, that enabled us to record the research and experimentation tax credit relating to the entire calendar 2012 in the nine months ended April 30, 2013. Additionally, this same Federal tax legislation expired in December 2013 preventing us from recording a full research and experimentation tax credit for calendar 2014 thereby adversely affecting our effective tax rate for the nine months ended April 30, 2014. This adverse impact was partially offset by the recognition of tax benefits upon resolution of income tax uncertainties.
	For the nine months ended April 30, 2014 and 2013, approximately 3% and 4%, respectively, of our income before income taxes was generated from our operations in Canada, Singapore, the Netherlands, and for the nine months ended April 30, 2014 as a result of the Jet Prep Acquisition, Israel. Collectively, these operations had an overall effective tax rate of 27.6% and 10.1% for the nine months ended April 30, 2014 and 2013, respectively. All of these locations have lower statutory income tax rates compared to the United States. The lower effective tax rate for the nine months ended April 30, 2013 was the result of the recording of a tax benefit in our third quarter of fiscal 2013 due to removing a valuation allowance on our net operating loss carryforwards (“NOLs”) in the Netherlands as a result of the simultaneous finalization in March 2013 of an IRS examination in the United States and a Dutch tax authority examination in the Netherlands. Additionally, the effective tax rate for the nine months ended April 30, 2013 was favorably affected by the recognition of tax benefits upon resolution of income tax uncertainties.
	We record liabilities for an unrecognized tax benefit when a tax benefit for an uncertain tax position is taken or expected to be taken on a tax return, but is not recognized in our Condensed Consolidated Financial Statements because it does not meet the more-likely-than-not recognition threshold that the uncertain tax position would be sustained upon examination by the applicable taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon settlement with the tax authorities. Any adjustments upon resolution of income tax uncertainties are recognized in our results of operations.
	A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits is as follows:
		Unrecognized
		Tax Benefits
	Unrecognized tax benefits on July 31, 2012	$	124,000
	Activity during fiscal 2013	—
	Unrecognized tax benefits on July 31, 2013	124,000
	Lapse of statute of limitations	(124,000		)
	Unrecognized tax benefits on April 30, 2014	$	—
	Generally, the Company is no longer subject to federal, state or foreign income tax examinations for fiscal years ended prior to July 31, 2006.
	Our policy is to record potential interest and penalties related to income tax positions in interest expense and general and administrative expense, respectively, in our Condensed Consolidated Financial Statements. However, such amounts have been relatively insignificant due to the amount of our unrecognized tax benefits relating to uncertain tax positions.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Apr. 30, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	Note 12.                          Commitments and Contingencies
	Long-Term Contractual Obligations
	As of April 30, 2014, aggregate annual payments over the remaining fiscal year, the next four years and thereafter under our contractual obligations that have long-term components were as follows:
		Three Months
		Ending
		July 31,		Year Ending July 31,
		2014		2015		2016		2017		2018		Thereafter		Total
		(Amounts in thousands)
	Maturity of the credit facility	$	—	$	—	$	—	$	—	$	—	$	64,500	$	64,500
	Expected interest payments under the credit facility (1)	305		1,219		1,219		1,219		1,219		711		5,892
	Minimum commitments under noncancelable operating leases	1,011		3,434		2,442		1,757		1,360		3,760		13,764
	Compensation agreements	1,192		6,074		1,496		600		350		846		10,558
	Contingent consideration (2)	—		177		629		1,120		1,609		4,465		8,000
	Assumed contingent liability (3)			143		318		549		711		465		2,186
	Deferred compensation and other	14		58		43		41		36		27		219
	Total contractual obligations	$	2,522	$	11,105	$	6,147	$	5,286	$	5,285	$	74,774	$	105,119
	(1) The expected interest payments under our credit facility reflect an interest rate of 1.89%, which was our weighted average interest rate on outstanding borrowings at April 30, 2014.
	(2) These future potential payments of contingent consideration relate to the Jet Prep Acquisition, as further explained below, and are reflected in the April 30, 2014 Consolidated Balance Sheet at its net present value of $5,026 using a discount rate of 11.5%.
	(3) These future potential payments of an assumed contingent liability relate to the Jet Prep Acquisition, as further explained below, and are reflected in the April 30, 2014 Consolidated Balance Sheet at its net present value of $1,045 using a discount rate of 11.5%.
	Operating Leases
	Minimum commitments under operating leases include minimum rental commitments for our leased manufacturing facilities, warehouses, office space and equipment.
	Compensation Agreements
	We have previously entered into various severance contracts with executives of the Company, including our Corporate executive officers and our subsidiary Chief Executive Officers, which define certain compensation arrangements relating to various employment termination scenarios. Additionally, we have previously entered into multi-year employment agreements with certain executive officers of businesses we have acquired.
	Contingent Consideration and Assumed Contingent Liability
	In relation to the Jet Prep Acquisition on November 5, 2013, we have recorded a $5,026,000 liability for the estimated fair value of contingent consideration payable to the sellers and a $1,045,000 liability for the estimated fair value of an assumed contingent obligation payable to the Israeli Government, as further described in Notes 3 and 6 to the Condensed Consolidated Financial Statements, which will be payable based on future sales of the Jet Prep Business (above a minimum threshold with respect to the contingent consideration liability).  As such, the estimates of the annual required payments as well as the fair value of these contingent liabilities are subjective in nature and highly dependent on future sales projections. Additionally, since we will be continually re-measuring the contingent consideration liability and the assumed contingent obligation at each balance sheet date and recording changes in the respective fair values through our Condensed Consolidated Statements of Income, we may potentially have significant earnings volatility in our future results of operations until the completion of the seven year period with respect to the contingent consideration liability and until the assumed contingent obligation is satisfied, or until the sales of the Jet Prep Ltd. products no longer exist.
	Deferred Compensation and Other
	Deferred compensation and other primarily includes deferred compensation arrangements for certain former Medivators directors and officers and is recorded in other long-term liabilities.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Apr. 30, 2014
Accumulated Other Comprehensive Income (Loss)	'
Accumulated Other Comprehensive Income (Loss)	'
	Note 13.                          Accumulated Other Comprehensive Income (Loss)
	The components and changes in accumulated other comprehensive income (loss) for the three and nine months ended April 30, 2014 and 2013 were as follows:
		Three Months Ended									Nine Months Ended
		April 30, 2014									April 30, 2014
		Foreign									Foreign
		Currency			Interest Rate						Currency			Interest Rate
		Translation			Swap						Translation			Swap
		Adjustments			Agreements			Total			Adjustments			Agreements			Total
	Beginning balance	$	9,406,000		$	—		$	9,406,000		$	11,080,000		$	(103,000	)	$	10,977,000
	Other comprehensive income (loss) before reclassifications	163,000			—			163,000			(1,511,000		)	(47,000		)	(1,558,000		)
	Income tax effect on other comprehensive loss before reclassification	—			—			—			—			17,000			17,000
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	—			—			—			—			96,000			96,000
	Reclassification adjustments for ineffective hedge on interest rate swap included in net income during the period	—			—			—			—			113,000			113,000
	Income tax effect on reclassification adjustments	—			—			—			—			(76,000		)	(76,000		)
	Ending balance	$	9,569,000		$	—		$	9,569,000		$	9,569,000		$	—		$	9,569,000
		Three Months Ended									Nine Months Ended
		April 30, 2013									April 30, 2013
		Foreign									Foreign
		Currency			Interest Rate						Currency			Interest Rate
		Translation			Swap						Translation			Swap
		Adjustments			Agreements			Total			Adjustments			Agreements			Total
	Beginning balance	$	8,540,000		$	(145,000	)	$	8,395,000		$	8,385,000		$	(210,000	)	$	8,175,000
	Other comprehensive loss before reclassifications	(243,000		)	(60,000		)	(303,000		)	(32,000		)	(74,000		)	(106,000		)
	Income tax effect on other comprehensive loss before reclassification	51,000			22,000			73,000			(5,000		)	27,000			22,000
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the periods	—			53,000			53,000			—			168,000			168,000
	Income tax effect on reclassification adjustments	—			(22,000		)	(22,000		)	—			(63,000		)	(63,000		)
	Ending balance	$	8,348,000		$	(152,000	)	$	8,196,000		$	8,348,000		$	(152,000	)	$	8,196,000

Operating_Segments

Operating Segments	9 Months Ended
	Apr. 30, 2014
Operating Segments	'
Operating Segments	'
	Note 14.                          Operating Segments
	Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products.
	In accordance with FASB ASC Topic 280, “Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and operating income.
	During the fourth quarter of fiscal 2013, we changed our internal reporting processes by combining our Therapeutic Filtration and Chemistries operating segments, previously reported in the Other reporting segment, with our Water Purification and Filtration reporting segment to reflect the way the Company, through its executive management, manages, allocates resources and measures the performance of its businesses. All periods presented have been recast to reflect these changes.
	None of our customers accounted for 10% or more of our consolidated net sales for the nine months ended April 30, 2014 and 2013, except for DaVita Inc. (“DaVita”), which accounted for approximately 10.5%, or approximately $37,595,000, for the nine months ended April 30, 2014 and approximately 10.5%, or $32,785,000, for the nine months ended April 30, 2013, of our consolidated net sales. For the nine months ended April 30, 2014, DaVita accounted for approximately 24.9% and 36.1% of our net sales in our Water Purification and Filtration and Dialysis segments, respectively. Another large customer accounted for approximately 22.1% of our Water Purification and Filtration segment net sales for the nine months ended April 30, 2014. Combined, these two customers accounted for approximately 17.9% of our consolidated net sales for the nine months ended April 30, 2014.
	The Company’s segments are as follows:
	Endoscopy, which includes medical device reprocessing systems, disinfectants, detergents and other supplies used to high-level disinfect flexible endoscopes. This segment also offers disposable infection control products intended to eliminate the challenges associated with proper cleaning and high-level disinfection of numerous reusable components used in gastrointestinal endoscopy procedures. Additionally, this segment includes technical maintenance service on its products.
	Water Purification and Filtration, which includes water purification equipment design and manufacturing, project management, installation, maintenance, deionization and mixing systems, as well as hollow fiber membrane filtration and separation technologies for high-purity fluid and separation applications for healthcare (with a large concentration in dialysis), pharmaceutical, biotechnology, research, beverage, semiconductor and other commercial industries. Additionally, this segment includes sterilants, disinfectants and decontamination services used in various applications for infection prevention and control.
	Healthcare Disposables, which includes single-use infection prevention and control products used principally in the dental market such as face masks, sterilization pouches, patient towels and bibs, self-sealing sterilization pouches, tray covers, surface barriers including eyewear, aprons and gowns, disinfectants, germicidal wipes, hand care products, gloves, sponges, cotton products, cups, needles and syringes, scalpels and blades, and saliva evacuators and ejectors. This segment also manufactures and provides biological and chemical indicators for sterility assurance monitoring services in the acute-care, alternate-care and dental markets.
	Four customers collectively accounted for approximately 51.9% of our Healthcare Disposables segment net sales and approximately 11.1% of our consolidated net sales for the nine months ended April 30, 2014.
	Dialysis, which includes disinfection/sterilization reprocessing equipment, sterilants, supplies and concentrates related to hemodialysis treatment of patients with acute kidney failure or chronic kidney failure associated with end-stage renal disease. Additionally, this segment includes technical maintenance service on its products.
	Other
	In accordance with quantitative thresholds established by ASC 280, the Specialty Packaging operating segment is reported in the Other reporting segment.
	Specialty Packaging, which includes specialty packaging and thermal control products, as well as related compliance training, for the safe transport of infectious and biological specimens and thermally sensitive pharmaceutical, medical and other products.
	The operating segments follow the same accounting policies used for our Condensed Consolidated Financial Statements as described in Note 2 to the 2013 Form 10-K.
	Information as to operating segments is summarized below:
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Net sales:
	Endoscopy	$	47,260,000		$	39,694,000		$	135,460,000		$	115,795,000
	Water Purification and Filtration	38,281,000			32,943,000			118,750,000			98,473,000
	Healthcare Disposables	25,506,000			22,674,000			76,471,000			66,968,000
	Dialysis	7,349,000			8,072,000			22,269,000			25,019,000
	Other	1,662,000			1,626,000			4,422,000			4,798,000
	Total	$	120,058,000		$	105,009,000		$	357,372,000		$	311,053,000
	Operating income:
	Endoscopy	$	8,482,000		$	7,241,000		$	24,884,000		$	24,386,000
	Water Purification and Filtration	6,292,000			3,649,000			19,457,000			11,995,000
	Healthcare Disposables	4,262,000			3,991,000			14,544,000			12,791,000
	Dialysis	1,515,000			1,990,000			5,275,000			6,478,000
	Other	319,000			306,000			555,000			644,000
		20,870,000			17,177,000			64,715,000			56,294,000
	General corporate expenses	(4,044,000		)	(2,954,000		)	(11,368,000		)	(9,236,000		)
	Interest expense, net	(535,000		)	(733,000		)	(1,809,000		)	(2,141,000		)
	Income before income taxes	$	16,291,000		$	13,490,000		$	51,538,000		$	44,917,000

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Apr. 30, 2014
Legal Proceedings	'
Legal Proceedings	'
	Note 15.                          Legal Proceedings
	In the normal course of business, we are subject to pending and threatened legal actions. It is our policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount of anticipated exposure can be reasonably estimated. We do not believe that any of these pending claims or legal actions will have a material effect on our business, financial condition, results of operations or cash flows.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Apr. 30, 2014
Stock-Based Compensation	'
Schedule of the income statement components of stock-based compensation expense recognized in the Condensed Consolidated Statements of Income	'
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Cost of sales	$	109,000		$	41,000		$	280,000		$	133,000
	Operating expenses:
	Selling	190,000			69,000			491,000			250,000
	General and administrative	1,104,000			802,000			3,158,000			2,396,000
	Research and development	19,000			7,000			49,000			27,000
	Total operating expenses	1,313,000			878,000			3,698,000			2,673,000
	Stock-based compensation before income taxes	1,422,000			919,000			3,978,000			2,806,000
	Income tax benefits	(499,000		)	(332,000		)	(1,404,000		)	(1,008,000		)
	Total stock-based compensation expense, net of tax	$	923,000		$	587,000		$	2,574,000		$	1,798,000
Summary of nonvested stock award activity	'
				Weighted
		Number of		Average
		Shares		Fair Value
	Nonvested stock awards at July 31, 2013	605,767		$	11.96
	Granted	247,136		31.84
	Canceled	(6,285	)	11.44
	Vested	(307,423	)	10.59
	Nonvested stock awards at April 30, 2014	539,195		$	21.86
Weighted-average assumptions used to estimate fair value of stock options granted using the Black-Scholes option valuation model	'
	Weighted-Average
	Black-Scholes Option	Nine Months Ended		Nine Months Ended
	Valuation Assumptions	April 30, 2014		April 30, 2013
	Dividend yield	0.28	%	0.37	%
	Expected volatility (1)	42.7	%	50.9	%
	Risk-free interest rate (2)	1.44	%	0.67	%
	Expected lives (in years) (3)	5		5
	(1) Volatility was based on historical closing prices of our common stock.
	(2) The U.S. Treasury rate on the expected life at the date of grant.
	(3) Based on historical exercise behavior.
Summary of stock option activity	'
				Weighted
		Number of		Average
		Shares		Exercise Price
	Outstanding at July 31, 2013	403,831		$	8.25
	Granted	30,000		31.81
	Exercised	(142,934	)	6.76
	Outstanding at April 30, 2014	290,897		$	11.41
	Exercisable at July 31, 2013	351,331		$	6.94
	Exercisable at April 30, 2014	225,897		$	7.83

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Apr. 30, 2014
Sterilator Company, Inc.	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'
		Preliminary
	Net Assets	Allocation
	Current assets	$	538,000
	Property, plant and equipment	535,000
	Amortizable intangible assets (9- year weighted average life):
	Customer relationships (11- year life)	130,000
	Technology (8- year life)	510,000
	Current liabilities	(321,000		)
	Deferred income tax liabilities	(260,000		)
	Net assets acquired	$	1,132,000
Jet Prep Ltd.	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'
		Preliminary
	Net Assets	Allocation
	Current assets	$	64,000
	Property, plant and equipment	65,000
	Amortizable intangible asset:
	Technology (7- year life)	5,050,000
	Current liabilities	(158,000		)
	Deferred income tax liabilities	(345,000		)
	Other long-term liabilities	(932,000		)
	Net assets acquired	$	3,744,000
Siemens' Hemodialysis Water Business	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'
		Final
	Net Assets	Allocation
	Current assets	$	728,000
	Property, plant and equipment	231,000
	Amortizable intangible assets:
	Customer relationships (12- year life)	4,310,000
	Current liabilities	(415,000		)
	Net assets acquired	$	4,854,000
Eagle Pure Water Systems, Inc.	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'
		Final
	Net Assets	Allocation
	Current assets	$	8,000
	Property, plant and equipment	70,000
	Amortizable intangible assets (3- year weighted average life):
	Customer relationships (3- year life)	150,000
	Brand names (3- year life)	18,000
	Non-compete agreement (5- year life)	32,000
	Current liabilities	(5,000		)
	Net assets acquired	$	273,000
SPS Medical Supply Corp.	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'
		Final
	Net Assets	Allocation
	Current assets	$	4,810,000
	Property, plant and equipment	3,801,000
	Amortizable intangible assets (9- year weighted average life):
	Customer relationships (10- year life)	8,120,000
	Brand names (5- year life)	760,000
	Technology (4- year life)	500,000
	Non-compete agreements (6- year life)	180,000
	Other assets	28,000
	Current liabilities	(2,784,000		)
	Noncurrent deferred income tax liabilities, net	(3,659,000		)
	Net assets acquired	$	11,756,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Apr. 30, 2014
Fair Value Measurements	'
Schedule of fair values of financial instruments measured on a recurring basis	'
		April 30, 2014
		Level 1			Level 2			Level 3		Total
	Assets:
	Cash and cash equivalents:
	Money markets	$	1,533,000		$	—		$	—	$	1,533,000
	Total assets	$	1,533,000		$	—		$	—	$	1,533,000
	Liabilities:
	Accrued expenses:
	Assumed contingent obligation	$	—		$	—		$	58,000	$	58,000
	Interest rate swap agreement	—			88,000			—		88,000
	Total accrued expenses	—			88,000			58,000		146,000
	Contingent consideration	—			—			5,026,000		5,026,000
	Other long-term liabilities:
	Assumed contingent obligation	—			—			987,000		987,000
	Interest rate swap agreement	—			9,000			—		9,000
	Total other long-term liabilities	—			9,000			987,000		996,000
	Total liabilities	$	—		$	97,000		$	6,071,000	$	6,168,000
		July 31, 2013
		Level 1			Level 2			Level 3		Total
	Assets:
	Cash and cash equivalents:
	Money markets	$	4,241,000		$	—		$	—	$	4,241,000
	Total assets	$	4,241,000		$	—		$	—	$	4,241,000
	Liabilities:
	Accrued expenses:
	Interest rate swap agreements	$	—		$	133,000		$	—	$	133,000
	Total accrued expenses	—			133,000			—		133,000
	Contingent consideration	—			—			45,000		45,000
	Other long-term liabilities:
	Interest rate swap agreements	—			29,000			—		29,000
	Total liabilities	$	—		$	162,000		$	45,000	$	207,000
Reconciliation of liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3)	'
										Jet Prep
		Byrne			Byrne			Jet Prep		Assumed
		Contingent			Price			Contingent		Contingent
		Consideration			Floor			Consideration		Obligation		Total
	Balance, July 31, 2012	$	1,500,000		$	1,037,000		$	—	$	—	$	2,537,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(313,000		)	—		—		(313,000		)
	Balance, October 31, 2012	1,500,000			724,000			—		—		2,224,000
	Total net unrealized gains included in general and administrative expense in earnings	(1,500,000		)	(410,000		)	—		—		(1,910,000		)
	Balance, January 31, 2013	—			314,000			—		—		314,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(59,000		)	—		—		(59,000		)
	Balance, April 30, 2013	—			255,000			—		—		255,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(210,000		)	—		—		(210,000		)
	Balance, July 31, 2013	—			45,000			—		—		45,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(44,000		)	—		—		(44,000		)
	Balance, October 31, 2013	—			1,000			—		—		1,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(1,000		)	—		—		(1,000		)
	Net purchases, issuances, sales and settlements	—			—			4,760,000		990,000		5,750,000
	Balance, January 31, 2014	—			—			4,760,000		990,000		5,750,000
	Total net unrealized losses included in general and administrative expense in earnings	—			—			266,000		55,000		321,000
	Balance, April 30, 2014	$	—		$	—		$	5,026,000	$	1,045,000	$	6,071,000

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Apr. 30, 2014
Intangible Assets and Goodwill	'
Schedule of intangible assets	'
		April 30, 2014
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	71,955,000	$	(29,655,000	)	$	42,300,000
	Technology	25,980,000		(10,820,000		)	15,160,000
	Brand names	12,680,000		(9,085,000		)	3,595,000
	Non-compete agreements	3,129,000		(693,000		)	2,436,000
	Patents and other registrations	1,973,000		(750,000		)	1,223,000
		115,717,000		(51,003,000		)	64,714,000
	Trademarks and trade names	9,267,000		—			9,267,000
	Total intangible assets	$	124,984,000	$	(51,003,000	)	$	73,981,000
		July 31, 2013
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	72,142,000	$	(25,379,000	)	$	46,763,000
	Technology	21,006,000		(9,642,000		)	11,364,000
	Brand names	12,680,000		(8,045,000		)	4,635,000
	Non-compete agreements	3,159,000		(541,000		)	2,618,000
	Patents and other registrations	1,768,000		(606,000		)	1,162,000
		110,755,000		(44,213,000		)	66,542,000
	Trademarks and trade names	9,387,000		—			9,387,000
	Total intangible assets	$	120,142,000	$	(44,213,000	)	$	75,929,000
Schedule of estimated amortization expense of intangible assets for remainder of fiscal 2014 and the next five years	'
	Three month period ending July 31, 2014	$	2,879,000
	Fiscal 2015	11,032,000
	Fiscal 2016	7,793,000
	Fiscal 2017	7,217,000
	Fiscal 2018	6,940,000
	Fiscal 2019	6,617,000
Schedule of changes in goodwill	'
				Water
				Purification			Healthcare							Total
		Endoscopy		and Filtration			Disposables		Dialysis		Other			Goodwill
	Balance, July 31, 2012	$	59,230,000	$	53,288,000		$	55,864,000	$	8,133,000	$	7,140,000		$	183,655,000
	Acquisitions	—		4,043,000			24,244,000		—		—			28,287,000
	Foreign currency translation	—		(152,000		)	—		—		(172,000		)	(324,000		)
	Balance, July 31, 2013	59,230,000		57,179,000			80,108,000		8,133,000		6,968,000			211,618,000
	Acquisitions	6,348,000		—			1,697,000		—		—			8,045,000
	Foreign currency translation	—		(370,000		)	—		—		(436,000		)	(806,000		)
	Balance, April 30, 2014	$	65,578,000	$	56,809,000		$	81,805,000	$	8,133,000	$	6,532,000		$	218,857,000

Warranties_Tables

Warranties (Tables)	9 Months Ended
	Apr. 30, 2014
Warranties	'
Summary of activity in warranty reserves	'
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Beginning balance	$	1,201,000		$	1,232,000		$	1,261,000		$	1,667,000
	Provisions	583,000			479,000			1,820,000			1,182,000
	Settlements	(567,000		)	(634,000		)	(1,863,000		)	(1,772,000		)
	Foreign currency translation	—			—			(1,000		)	—
	Ending balance	$	1,217,000		$	1,077,000		$	1,217,000		$	1,077,000

Earnings_Per_Common_Share_Tabl

Earnings Per Common Share (Tables)	9 Months Ended
	Apr. 30, 2014
Earnings Per Common Share	'
Schedule of computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities)	'
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Numerator for basic and diluted earnings per share:
	Net income	$	10,249,000		$	8,998,000		$	32,560,000		$	29,026,000
	Less income allocated to participating securities	(135,000		)	(137,000		)	(444,000		)	(454,000		)
	Net income available to common stockholders	$	10,114,000		$	8,861,000		$	32,116,000		$	28,572,000
	Denominator for basic and diluted earnings per share, as adjusted for participating securities:
	Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	40,813,778			40,365,939			40,716,018			40,201,691
	Dilutive effect of stock options using the treasury stock method and the average market price for the period	143,319			258,719			174,107			315,692
	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,957,097			40,624,658			40,890,125			40,517,383
	Earnings per share attributable to common stock:
	Basic earnings per share	$	0.25		$	0.22		$	0.79		$	0.71
	Diluted earnings per share	$	0.25		$	0.22		$	0.79		$	0.71
	Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive	30,000			—			—			—
Schedule of reconciliation of weighted average number of shares and common stock equivalents attributable to common stock to the Company's total weighted average number of shares and common stock equivalents including participating securities	'
		Three Months Ended				Nine Months Ended
		April 30,				April 30,
		2014		2013		2014		2013
	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,957,097		40,624,658		40,890,125		40,517,383
	Participating securities	544,752		626,415		566,545		646,104
	Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,501,849		41,251,073		41,456,670		41,163,487

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Apr. 30, 2014
Income Taxes	'
Schedule of reconciliation of the beginning and ending amounts of gross unrecognized tax benefits	'
		Unrecognized
		Tax Benefits
	Unrecognized tax benefits on July 31, 2012	$	124,000
	Activity during fiscal 2013	—
	Unrecognized tax benefits on July 31, 2013	124,000
	Lapse of statute of limitations	(124,000		)
	Unrecognized tax benefits on April 30, 2014	$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Apr. 30, 2014
Commitments and Contingencies	'
Schedule of aggregate annual required payments over the remaining fiscal year, the next four years and thereafter under contractual obligations that have long-term components	'
		Three Months
		Ending
		July 31,		Year Ending July 31,
		2014		2015		2016		2017		2018		Thereafter		Total
		(Amounts in thousands)
	Maturity of the credit facility	$	—	$	—	$	—	$	—	$	—	$	64,500	$	64,500
	Expected interest payments under the credit facility (1)	305		1,219		1,219		1,219		1,219		711		5,892
	Minimum commitments under noncancelable operating leases	1,011		3,434		2,442		1,757		1,360		3,760		13,764
	Compensation agreements	1,192		6,074		1,496		600		350		846		10,558
	Contingent consideration (2)	—		177		629		1,120		1,609		4,465		8,000
	Assumed contingent liability (3)			143		318		549		711		465		2,186
	Deferred compensation and other	14		58		43		41		36		27		219
	Total contractual obligations	$	2,522	$	11,105	$	6,147	$	5,286	$	5,285	$	74,774	$	105,119
	(1) The expected interest payments under our credit facility reflect an interest rate of 1.89%, which was our weighted average interest rate on outstanding borrowings at April 30, 2014.
	(2) These future potential payments of contingent consideration relate to the Jet Prep Acquisition, as further explained below, and are reflected in the April 30, 2014 Consolidated Balance Sheet at its net present value of $5,026 using a discount rate of 11.5%.
	(3) These future potential payments of an assumed contingent liability relate to the Jet Prep Acquisition, as further explained below, and are reflected in the April 30, 2014 Consolidated Balance Sheet at its net present value of $1,045 using a discount rate of 11.5%.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Apr. 30, 2014
Accumulated Other Comprehensive Income (Loss)	'
Schedule of the components and changes in accumulated other comprehensive income (loss)	'
		Three Months Ended									Nine Months Ended
		April 30, 2014									April 30, 2014
		Foreign									Foreign
		Currency			Interest Rate						Currency			Interest Rate
		Translation			Swap						Translation			Swap
		Adjustments			Agreements			Total			Adjustments			Agreements			Total
	Beginning balance	$	9,406,000		$	—		$	9,406,000		$	11,080,000		$	(103,000	)	$	10,977,000
	Other comprehensive income (loss) before reclassifications	163,000			—			163,000			(1,511,000		)	(47,000		)	(1,558,000		)
	Income tax effect on other comprehensive loss before reclassification	—			—			—			—			17,000			17,000
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	—			—			—			—			96,000			96,000
	Reclassification adjustments for ineffective hedge on interest rate swap included in net income during the period	—			—			—			—			113,000			113,000
	Income tax effect on reclassification adjustments	—			—			—			—			(76,000		)	(76,000		)
	Ending balance	$	9,569,000		$	—		$	9,569,000		$	9,569,000		$	—		$	9,569,000
		Three Months Ended									Nine Months Ended
		April 30, 2013									April 30, 2013
		Foreign									Foreign
		Currency			Interest Rate						Currency			Interest Rate
		Translation			Swap						Translation			Swap
		Adjustments			Agreements			Total			Adjustments			Agreements			Total
	Beginning balance	$	8,540,000		$	(145,000	)	$	8,395,000		$	8,385,000		$	(210,000	)	$	8,175,000
	Other comprehensive loss before reclassifications	(243,000		)	(60,000		)	(303,000		)	(32,000		)	(74,000		)	(106,000		)
	Income tax effect on other comprehensive loss before reclassification	51,000			22,000			73,000			(5,000		)	27,000			22,000
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the periods	—			53,000			53,000			—			168,000			168,000
	Income tax effect on reclassification adjustments	—			(22,000		)	(22,000		)	—			(63,000		)	(63,000		)
	Ending balance	$	8,348,000		$	(152,000	)	$	8,196,000		$	8,348,000		$	(152,000	)	$	8,196,000

Operating_Segments_Tables

Operating Segments (Tables)	9 Months Ended
	Apr. 30, 2014
Operating Segments	'
Information as to operating segments	'
		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2014			2013			2014			2013
	Net sales:
	Endoscopy	$	47,260,000		$	39,694,000		$	135,460,000		$	115,795,000
	Water Purification and Filtration	38,281,000			32,943,000			118,750,000			98,473,000
	Healthcare Disposables	25,506,000			22,674,000			76,471,000			66,968,000
	Dialysis	7,349,000			8,072,000			22,269,000			25,019,000
	Other	1,662,000			1,626,000			4,422,000			4,798,000
	Total	$	120,058,000		$	105,009,000		$	357,372,000		$	311,053,000
	Operating income:
	Endoscopy	$	8,482,000		$	7,241,000		$	24,884,000		$	24,386,000
	Water Purification and Filtration	6,292,000			3,649,000			19,457,000			11,995,000
	Healthcare Disposables	4,262,000			3,991,000			14,544,000			12,791,000
	Dialysis	1,515,000			1,990,000			5,275,000			6,478,000
	Other	319,000			306,000			555,000			644,000
		20,870,000			17,177,000			64,715,000			56,294,000
	General corporate expenses	(4,044,000		)	(2,954,000		)	(11,368,000		)	(9,236,000		)
	Interest expense, net	(535,000		)	(733,000		)	(1,809,000		)	(2,141,000		)
	Income before income taxes	$	16,291,000		$	13,490,000		$	51,538,000		$	44,917,000

Basis_of_Presentation_Details

Basis of Presentation (Details)	9 Months Ended	12 Months Ended
	Apr. 30, 2014	Jul. 31, 2013
	segment	company
	company
Basis of Presentation	'	'
Number of principal operating companies	5	5
Business Description	'	'
Number of operating segments	5	'
Additional common stock issued as stock dividend (in shares)	'	15,044,000
Stock split ratio	'	1.5
Percentage of stock dividend paid	'	50.00%
Medivators	'	'
Business Description	'	'
Number of foreign subsidiaries	2	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'	'	'
Stock-based compensation before income taxes	$1,422,000	$919,000	$3,978,000	$2,806,000
Income tax benefits	-499,000	-332,000	-1,404,000	-1,008,000
Total stock-based compensation expense, net of tax	923,000	587,000	2,574,000	1,798,000
Cost of sales	'	'	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'	'	'
Stock-based compensation before income taxes	109,000	41,000	280,000	133,000
Operating expenses: Selling	'	'	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'	'	'
Stock-based compensation before income taxes	190,000	69,000	491,000	250,000
Operating expenses: General and administrative	'	'	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'	'	'
Stock-based compensation before income taxes	1,104,000	802,000	3,158,000	2,396,000
Operating expenses: Research and development	'	'	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'	'	'
Stock-based compensation before income taxes	19,000	7,000	49,000	27,000
Total operating expenses	'	'	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'	'	'
Stock-based compensation before income taxes	$1,313,000	$878,000	$3,698,000	$2,673,000

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	6 Months Ended	9 Months Ended			3 Months Ended		9 Months Ended
	Jan. 31, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Jul. 31, 2013
				Restricted shares	Stock options	Stock options	Stock options	Stock options	Stock options
Stock-Based Compensation	'	'	'	'	'	'	'	'	'
Total unrecognized stock-based compensation expense, before income taxes, related to total nonvested stock options and stock awards (in dollars)	'	$8,744,000	'	'	'	'	'	'	'
Remaining weighted average period over which unrecognized stock-based compensation expense is expected to be recognized	'	'19 months	'	'	'	'	'	'	'
Number of Shares	'	'	'	'	'	'	'	'	'
Nonvested stock awards at the beginning of the period (in shares)	'	'	'	605,767	'	'	'	'	'
Granted (in shares)	'	'	'	247,136	'	'	'	'	'
Cancelled (in shares)	'	'	'	-6,285	'	'	'	'	'
Vested (in shares)	'	'	'	-307,423	'	'	'	'	'
Nonvested stock awards at the end of the period (in shares)	'	'	'	539,195	'	'	'	'	'
Weighted Average Fair Value	'	'	'	'	'	'	'	'	'
Nonvested stock awards at the beginning of the period (in dollars per share)	'	'	'	$11.96	'	'	'	'	'
Granted (in dollars per share)	'	'	'	$31.84	'	'	'	'	'
Cancelled (in dollars per share)	'	'	'	$11.44	'	'	'	'	'
Vested (in dollars per share)	'	'	'	$10.59	'	'	'	'	'
Nonvested stock awards at the end of the period (in dollars per share)	'	'	'	$21.86	'	'	'	'	'
Weighted-Average Black-Scholes Option Valuation Assumptions	'	'	'	'	'	'	'	'	'
Dividend yield (as a percent)	'	'	'	'	'	'	0.28%	0.37%	'
Expected volatility (as a percent)	'	'	'	'	'	'	42.70%	50.90%	'
Risk-free interest rate (as a percent)	'	'	'	'	'	'	1.44%	0.67%	'
Expected lives	'	'	'	'	'	'	'5 years	'5 years	'
Stock options, additional disclosure	'	'	'	'	'	'	'	'	'
Weighted average fair value of all options granted (in dollars per share)	'	'	'	'	'	'	$12.08	$7.27	'
Aggregate intrinsic value of all options exercised (in dollars)	'	'	'	'	1,328,000	537,000	3,747,000	4,025,000	'
Number of Shares	'	'	'	'	'	'	'	'	'
Outstanding at the beginning of the period (in shares)	'	'	'	'	'	'	403,831	'	'
Options granted (in shares)	'	'	'	'	'	'	30,000	52,500	'
Exercised (in shares)	'	'	'	'	'	'	-142,934	'	'
Outstanding at the end of the period (in shares)	'	'	'	'	290,897	'	290,897	'	'
Exercisable at the end of the period (in shares)	'	'	'	'	225,897	'	225,897	'	351,331
Weighted Average Exercise Price	'	'	'	'	'	'	'	'	'
Outstanding at the beginning of the period (in dollars per share)	'	'	'	'	'	'	$8.25	'	'
Granted (in dollars per share)	'	'	'	'	'	'	$31.81	'	'
Exercised (in dollars per share)	'	'	'	'	'	'	$6.76	'	'
Outstanding at the end of the period (in dollars per share)	'	'	'	'	$11.41	'	$11.41	'	'
Exercisable at the end of the period (in dollars per share)	'	'	'	'	$7.83	'	$7.83	'	$6.94
Stock-based awards, additional disclosure	'	'	'	'	'	'	'	'	'
Reissued shares from treasury stock for exercise of stock options and grant of stock awards (in shares)	474,266	'	'	'	'	'	'	'	'
Deduction in income tax due to exercise of options and vesting of restricted stock (in dollars)	'	5,124,000	3,073,000	'	'	'	'	'	'
Increase in additional paid-in capital due to excess tax benefit on stock-based compensation expense (in dollars)	'	$3,815,000	$1,986,000	'	'	'	'	'	'

Acquisitions_Details

Acquisitions (Details) (Puri Core International Limited, Subsequent Events, USD $)	0 Months Ended
	Jun. 03, 2014
Acquisitions	'
Pre-acquisition annual revenues	$25,000,000
Forecast	'
Acquisitions	'
Total consideration for the transaction, excluding transaction costs	$26,892,000

Acquisitions_Details_2

Acquisitions (Details 2) (USD $)	Apr. 30, 2014	Jul. 31, 2013	Jul. 31, 2012	Jan. 07, 2014	Jan. 07, 2014	Jan. 07, 2014
				Sterilator Company, Inc.	Sterilator Company, Inc.	Sterilator Company, Inc.
				Crosstex' subsidiary	Crosstex' subsidiary	Crosstex' subsidiary
				project	Customer relationships	Technology
Acquisitions	'	'	'	'	'	'
Total consideration for the transaction	'	'	'	$2,829,000	'	'
Net Assets	'	'	'	'	'	'
Current assets	'	'	'	538,000	'	'
Property, plant and equipment	'	'	'	535,000	'	'
Amortizable intangible assets	'	'	'	'	130,000	510,000
Current liabilities	'	'	'	-321,000	'	'
Deferred income tax liabilities	'	'	'	-260,000	'	'
Net assets acquired	'	'	'	1,132,000	'	'
Amortizable intangible assets, useful life	'	'	'	'9 years	'11 years	'8 years
Number of in-process research and development projects acquired	'	'	'	0	'	'
Goodwill	218,857,000	211,618,000	183,655,000	1,697,000	'	'
Goodwill deductible for income tax purposes	'	'	'	$0	'	'

Acquisitions_Details_3

Acquisitions (Details 3) (USD $)

Apr. 30, 2014

Jul. 31, 2013

Jul. 31, 2012

Nov. 05, 2013

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Nov. 05, 2013

Nov. 05, 2013

Nov. 05, 2013

Nov. 05, 2013

Nov. 05, 2013

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Medivators B.V. subsidiary

project

Contingent consideration

Accrued expenses

Other long-term liabilities

Technology

Contingent consideration, payable to sellers

Contingent consideration, payable to Israeli Government

Contingent consideration, payable to Israeli Government

Contingent consideration, payable to Israeli Government

Minimum

Maximum

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

Transaction costs

'

'

'

$200,000

'

'

'

'

'

'

'

'

'

Total consideration for the transaction, excluding transaction costs

'

'

'

5,332,000

'

'

'

'

'

'

'

'

'

Contingent consideration liability

'

'

'

4,760,000

5,026,000

5,026,000

'

'

'

4,760,000

'

'

'

Period over which potential cash contingent consideration is payable

'

'

'

'7 years

'

'

'

'

'

'

'

'

'

Assumed contingent obligation

'

'

'

'

1,045,000

'

58,000

987,000

'

'

'

'

'

Increase in goodwill

'

'

'

'

'

'

'

'

'

4,760,000

990,000

'

'

Increase in accrued expenses

'

'

'

'

'

'

'

'

'

'

58,000

'

'

Increase in other long-term liabilities

'

'

'

'

'

'

'

'

'

'

932,000

'

'

Liabilities assumed

'

'

'

'

'

'

'

'

'

'

810,000

'

'

Israeli Government's rate of return on investment

'

'

'

'

'

'

'

'

'

'

'

1

9

Net Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

Current assets

'

'

'

64,000

'

'

'

'

'

'

'

'

'

Property, plant and equipment

'

'

'

65,000

'

'

'

'

'

'

'

'

'

Amortizable intangible assets

'

'

'

'

'

'

'

'

5,050,000

'

'

'

'

Current liabilities

'

'

'

-158,000

'

'

'

'

'

'

'

'

'

Deferred income tax liabilities

'

'

'

-345,000

'

'

'

'

'

'

'

'

'

Other long-term liabilities

'

'

'

-932,000

'

'

'

'

'

'

'

'

'

Net assets acquired

'

'

'

3,744,000

'

'

'

'

'

'

'

'

'

Amortizable intangible assets, useful life

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

Number of in-process research and development projects acquired

'

'

'

0

'

'

'

'

'

'

'

'

'

Goodwill

218,857,000

211,618,000

183,655,000

6,348,000

'

'

'

'

'

'

'

'

'

Goodwill deductible for income tax purposes

'

'

'

$0

'

'

'

'

'

'

'

'

'

Acquisitions_Details_4

Acquisitions (Details 4) (Siemens' Hemodialysis Water Business, Mar Cor subsidiary, USD $)	0 Months Ended
	Mar. 22, 2013
	project
Acquisitions	'
Transaction costs	$362,000
Total consideration for the transaction, excluding transaction costs	8,300,000
Net Assets	'
Current assets	728,000
Property, plant and equipment	231,000
Current liabilities	-415,000
Net assets acquired	4,854,000
Number of in-process research and development projects acquired	0
Goodwill deductible for income tax purposes	3,446,000
Customer relationships	'
Net Assets	'
Amortizable intangible assets	4,310,000
Amortizable intangible assets, useful life	'12 years
Minimum	'
Acquisitions	'
Number of dialysis customers	600
Revenues generated by acquiree in latest fiscal year before the business acquisition	$9,000,000

Acquisitions_Details_5

Acquisitions (Details 5) (Eagle Pure Water Systems, Inc., Mar Cor, USD $)	0 Months Ended
	Dec. 31, 2012
	project
Acquisitions	'
Revenues generated by acquiree in latest fiscal year before the business acquisition	$500,000
Consideration for the transaction	870,000
Net Assets	'
Current assets	8,000
Property, plant and equipment	70,000
Current liabilities	-5,000
Net assets acquired	273,000
Amortizable intangible assets, useful life	'3 years
Number of in-process research and development projects acquired	0
Goodwill deductible for income tax purposes	597,000
Customer relationships	'
Net Assets	'
Amortizable intangible assets	150,000
Amortizable intangible assets, useful life	'3 years
Brand names	'
Net Assets	'
Amortizable intangible assets	18,000
Amortizable intangible assets, useful life	'3 years
Non-compete agreement	'
Net Assets	'
Amortizable intangible assets	$32,000
Amortizable intangible assets, useful life	'5 years

Acquisitions_Details_6

Acquisitions (Details 6) (Polyp Trap, Medivators, USD $)	1 Months Ended
	Dec. 13, 2012
Polyp Trap | Medivators	'
Acquisitions	'
Consideration for the transaction	$486,000

Acquisitions_Details_7

Acquisitions (Details 7) (USD $)	Apr. 30, 2014	Jul. 31, 2013	Jul. 31, 2012	Nov. 03, 2012	Nov. 03, 2012	Nov. 03, 2012	Nov. 03, 2012	Nov. 03, 2012	Nov. 03, 2012	Nov. 03, 2012
				SPS Medical Supply Corp. and SPS manufacturing and warehouse facility	SPS Medical Supply Corp. and SPS manufacturing and warehouse facility	SPS Medical Supply Corp. and SPS manufacturing and warehouse facility	SPS Medical Supply Corp. and SPS manufacturing and warehouse facility	SPS Medical Supply Corp. and SPS manufacturing and warehouse facility	SPS Medical Supply Corp	SPS Medical manufacturing, warehouse and office facility in Rochester, New York
				Crosstex subsidiary	Crosstex subsidiary	Crosstex subsidiary	Crosstex subsidiary	Crosstex subsidiary	Crosstex subsidiary	Crosstex subsidiary
				project	Customer relationships	Brand names	Technology	Non-compete agreement
Acquisitions	'	'	'	'	'	'	'	'	'	'
Revenues generated by acquiree in latest fiscal year before the business acquisition	'	'	'	'	'	'	'	'	$17,500,000	'
Transaction costs	'	'	'	'	'	'	'	'	157,000	'
Total consideration for the transaction, excluding transaction costs	'	'	'	'	'	'	'	'	32,500,000	'
Consideration for the transaction	'	'	'	'	'	'	'	'	'	3,500,000
Net Assets	'	'	'	'	'	'	'	'	'	'
Current assets	'	'	'	4,810,000	'	'	'	'	'	'
Property, plant and equipment	'	'	'	3,801,000	'	'	'	'	'	'
Amortizable intangible assets	'	'	'	'	8,120,000	760,000	500,000	180,000	'	'
Other assets, Noncurrent	'	'	'	28,000	'	'	'	'	'	'
Current liabilities	'	'	'	-2,784,000	'	'	'	'	'	'
Noncurrent deferred income tax liabilities, net	'	'	'	-3,659,000	'	'	'	'	'	'
Net assets acquired	'	'	'	11,756,000	'	'	'	'	'	'
Amortizable intangible assets, useful life	'	'	'	'9 years	'10 years	'5 years	'4 years	'6 years	'	'
Number of in-process research and development projects acquired	'	'	'	0	'	'	'	'	'	'
Goodwill	218,857,000	211,618,000	183,655,000	24,244,000	'	'	'	'	'	'
Goodwill deductible for income tax purposes	'	'	'	$0	'	'	'	'	'	'

Derivatives_Details

Derivatives (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended	0 Months Ended
	Feb. 29, 2012	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Jan. 31, 2014	Aug. 08, 2012	Aug. 08, 2012	Aug. 08, 2012	Aug. 08, 2012
	lender	Foreign currency forward contracts	Foreign currency forward contracts	Foreign currency forward contracts	Foreign currency forward contracts	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements
		Fair value hedge instruments	Fair value hedge instruments	Fair value hedge instruments	Fair value hedge instruments	Term Loan Facility	Cash flow hedge instruments	Cash flow hedge instruments	Cash flow hedge instruments	Cash flow hedge instruments
		contract		contract			Term Loan Facility	Term Loan Facility	Revolving Credit Facility	Revolving Credit Facility
								One month LIBOR		One month LIBOR
Derivatives	'	'	'	'	'	'	'	'	'	'
Term of contracts	'	'	'	'1 month	'	'	'	'	'	'
Number of contracts	'	3	'	3	'	'	'	'	'	'
Aggregate value of contracts	'	$11,874,000	'	$11,874,000	'	'	'	'	'	'
Term of renewed contracts	'	'	'	'1 month	'	'	'	'	'	'
Net currency conversion gain (loss), net of tax	'	26,000	-2,000	-70,000	-46,000	'	'	'	'	'
Number of existing senior lenders of debt, whose variable interest cash flows will be exchanged by the entity with fixed interest cash flows	1	'	'	'	'	'	'	'	'	'
Borrowing initially hedged	'	'	'	'	'	'	40,000,000	'	25,000,000	'
Reference rate, description	'	'	'	'	'	'	'	'one month LIBOR	'	'one month LIBOR
Quarterly reduction in borrowings hedged	'	'	'	'	'	'	2,500,000	'	'	'
Semi-annual reduction in borrowings hedged	'	'	'	'	'	'	'	'	5,000,000	'
Interest rate (as a percent)	'	'	'	'	'	'	'	0.66%	'	0.50%
Fair value of interest rate swap recognized in interest expense	'	'	'	'	'	$113,000	'	'	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	1 Months Ended	0 Months Ended				0 Months Ended			0 Months Ended
	Feb. 29, 2012	Nov. 05, 2013	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Nov. 05, 2013	Apr. 30, 2014	Nov. 05, 2013	Nov. 05, 2013	Nov. 05, 2013
	lender	Medivators B.V. subsidiary	Medivators B.V. subsidiary	Medivators B.V. subsidiary	Medivators B.V. subsidiary	Level 3	Level 3	Level 3	Level 3	Level 3
		Jet Prep Ltd.	Jet Prep Ltd.	Jet Prep Ltd.	Jet Prep Ltd.	Medivators B.V. subsidiary	Medivators B.V. subsidiary	Medivators B.V. subsidiary	Medivators B.V. subsidiary	Medivators B.V. subsidiary
				Contingent consideration	Assumed contingent obligation	Jet Prep Ltd.	Jet Prep Ltd.	Jet Prep Ltd.	Jet Prep Ltd.	Jet Prep Ltd.
						item		Minimum	Contingent consideration	Assumed contingent obligation
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis	'	'	'	'	'	'	'	'	'	'
Number of existing senior lenders of debt, whose variable interest cash flows will be exchanged by the entity with fixed interest cash flows	1	'	'	'	'	'	'	'	'	'
Contingent consideration liability	'	$4,760,000	$5,026,000	'	'	$4,760,000	$5,026,000	'	'	'
Assumed contingent obligation	'	'	1,045,000	'	'	990,000	1,045,000	810,000	'	'
Contingent consideration period	'	'7 years	'	'	'	'7 years	'	'	'	'
Discount rate of cash flow projections (as a percent)	'	'	'	'	'	'	'	'	11.50%	11.50%
Number of liabilities adjusted periodically by recording changes in the fair value through condensed consolidated statements of Income	'	'	'	'	'	2	'	'	'	'
Total potential contingent consideration payments, low end of range	'	'	'	0	0	'	'	'	'	'
Total potential contingent consideration payments, high end of range	'	'	'	$12,000,000	$2,430,000	'	'	'	'	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	12 Months Ended	0 Months Ended	1 Months Ended
	Jul. 31, 2013	Aug. 02, 2011	Nov. 30, 2013	Jul. 29, 2011
		Recurring basis	Recurring basis	Recurring basis
		Level 3	Level 3	Level 3
		Byrne Medical Business	Byrne Medical Business	Byrne Medical Business
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis	'	'	'	'
Initial contingent consideration liability	'	$2,700,000	'	'
Initial price floor	'	3,000,000	'	'
Price floor period	'	'3 years	'	'
Contingent consideration period	'	'2 years	'	'
Discount rate of cash flow projections (as a percent)	'	14.00%	'	'
Stock split ratio	1.5	1.5	'	'
Stock consideration (in shares)	'	902,528	'	'
Stock price (in dollars per share)	'	'	'	$11.08
Total potential contingent consideration payments, high end of range	'	$10,000,000	$6,666,666	'
Cantel common stock placed in escrow at the time of acquisition	'	902,528	'	'
Proportion of shares released from escrow	'	'	0.33	'
Proportion of estimated contingent consideration reduced as a result of shares released from escrow	'	'	0.33	'

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (Recurring basis, USD $)	Apr. 30, 2014	Jul. 31, 2013
Level 1	'	'
Assets:	'	'
Total assets	$1,533,000	$4,241,000
Level 1 | Money markets | Cash and cash equivalents	'	'
Assets:	'	'
Money markets	1,533,000	4,241,000
Level 2	'	'
Liabilities:	'	'
Total accrued expenses	88,000	133,000
Total other long-term liabilities	9,000	'
Total liabilities	97,000	162,000
Level 2 | Interest rate swap agreements | Accrued expenses	'	'
Liabilities:	'	'
Interest rate swap agreement	88,000	133,000
Level 2 | Interest rate swap agreements | Other long-term liabilities	'	'
Liabilities:	'	'
Interest rate swap agreement	9,000	29,000
Level 3	'	'
Liabilities:	'	'
Total accrued expenses	58,000	'
Total other long-term liabilities	987,000	'
Total liabilities	6,071,000	45,000
Level 3 | Accrued expenses	'	'
Liabilities:	'	'
Assumed contingent obligation	58,000	'
Level 3 | Contingent consideration	'	'
Liabilities:	'	'
Contingent consideration	5,026,000	45,000
Level 3 | Other long-term liabilities	'	'
Liabilities:	'	'
Assumed contingent obligation	987,000	'
Total	'	'
Assets:	'	'
Total assets	1,533,000	4,241,000
Liabilities:	'	'
Total accrued expenses	146,000	133,000
Total other long-term liabilities	996,000	'
Total liabilities	6,168,000	207,000
Total | Accrued expenses	'	'
Liabilities:	'	'
Assumed contingent obligation	58,000	'
Total | Contingent consideration	'	'
Liabilities:	'	'
Contingent consideration	5,026,000	45,000
Total | Other long-term liabilities	'	'
Liabilities:	'	'
Assumed contingent obligation	987,000	'
Total | Interest rate swap agreements | Accrued expenses	'	'
Liabilities:	'	'
Interest rate swap agreement	88,000	133,000
Total | Interest rate swap agreements | Other long-term liabilities	'	'
Liabilities:	'	'
Interest rate swap agreement	9,000	29,000
Total | Money markets | Cash and cash equivalents	'	'
Assets:	'	'
Money markets	$1,533,000	$4,241,000

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details 4) (USD $)

3 Months Ended

3 Months Ended

Apr. 30, 2014

Jan. 31, 2014

Oct. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Jan. 31, 2014

Oct. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Jan. 31, 2013

Jul. 31, 2012

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Byrne Medical Business

Byrne Medical Business

Byrne Medical Business

Byrne Medical Business

Byrne Medical Business

Byrne Medical Business

Contingent Consideration

Contingent Consideration

Contingent Consideration

Contingent Consideration

Assumed Contingent Obligation

Assumed Contingent Obligation

Three-year price floor

Three-year price floor

Three-year price floor

Three-year price floor

Three-year price floor

Three-year price floor

Byrne Medical Business

Byrne Medical Business

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Jet Prep Ltd.

Reconciliation of liability measured and recorded at fair value on a recurring basis using Level 3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance

$5,750,000

$1,000

$45,000

$255,000

$314,000

$2,224,000

$2,537,000

$1,000

$45,000

$255,000

$314,000

$724,000

$1,037,000

$1,500,000

$1,500,000

$4,760,000

'

$990,000

'

Total net unrealized (gains) losses included in general and administrative expense in earnings

321,000

-1,000

-44,000

-210,000

-59,000

-1,910,000

-313,000

-1,000

-44,000

-210,000

-59,000

-410,000

-313,000

-1,500,000

'

266,000

'

55,000

'

Net purchases, issuances, sales and settlements

'

5,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,760,000

'

990,000

Ending balance

$6,071,000

$5,750,000

$1,000

$45,000

$255,000

$314,000

$2,224,000

'

$1,000

$45,000

$255,000

$314,000

$724,000

'

$1,500,000

$5,026,000

$4,760,000

$1,045,000

$990,000

Fair_Value_Measurements_Detail4

Fair Value Measurements (Details 5) (USD $)	9 Months Ended	12 Months Ended
	Apr. 30, 2014	Jul. 31, 2013
Fair Value Measurements	'	'
Impairment of long-lived assets, including goodwill and intangibles with indefinite lives	0	'
Minimum	'	'
Disclosure of Fair Value of Financial Instruments	'	'
Interest rate base	'One month LIBOR	'One month LIBOR
Maximum	'	'
Disclosure of Fair Value of Financial Instruments	'	'
Interest rate base	'Twelve month LIBOR	'Twelve month LIBOR

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Jul. 31, 2013
Intangible assets with finite lives:	'	'	'	'	'
Amortization expense	$2,637,000	$2,598,000	$7,882,000	$7,438,000	'
Gross	115,717,000	'	115,717,000	'	110,755,000
Accumulated Amortization	-51,003,000	'	-51,003,000	'	-44,213,000
Net	64,714,000	'	64,714,000	'	66,542,000
Intangible assets with indefinite lives:	'	'	'	'	'
Trademarks and trade names	9,267,000	'	9,267,000	'	9,387,000
Total intangible assets	'	'	'	'	'
Gross	124,984,000	'	124,984,000	'	120,142,000
Accumulated Amortization	-51,003,000	'	-51,003,000	'	-44,213,000
Net	73,981,000	'	73,981,000	'	75,929,000
Low end of range	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Estimated useful lives	'	'	'2 years	'	'
High end of range	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Estimated useful lives	'	'	'20 years	'	'
Weighted average	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Estimated useful lives	'	'	'11 years	'	'
Customer relationships	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Gross	71,955,000	'	71,955,000	'	72,142,000
Accumulated Amortization	-29,655,000	'	-29,655,000	'	-25,379,000
Net	42,300,000	'	42,300,000	'	46,763,000
Total intangible assets	'	'	'	'	'
Accumulated Amortization	-29,655,000	'	-29,655,000	'	-25,379,000
Technology	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Gross	25,980,000	'	25,980,000	'	21,006,000
Accumulated Amortization	-10,820,000	'	-10,820,000	'	-9,642,000
Net	15,160,000	'	15,160,000	'	11,364,000
Total intangible assets	'	'	'	'	'
Accumulated Amortization	-10,820,000	'	-10,820,000	'	-9,642,000
Brand names	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Gross	12,680,000	'	12,680,000	'	12,680,000
Accumulated Amortization	-9,085,000	'	-9,085,000	'	-8,045,000
Net	3,595,000	'	3,595,000	'	4,635,000
Total intangible assets	'	'	'	'	'
Accumulated Amortization	-9,085,000	'	-9,085,000	'	-8,045,000
Non-compete agreements	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Gross	3,129,000	'	3,129,000	'	3,159,000
Accumulated Amortization	-693,000	'	-693,000	'	-541,000
Net	2,436,000	'	2,436,000	'	2,618,000
Total intangible assets	'	'	'	'	'
Accumulated Amortization	-693,000	'	-693,000	'	-541,000
Patents and other registrations	'	'	'	'	'
Intangible assets with finite lives:	'	'	'	'	'
Gross	1,973,000	'	1,973,000	'	1,768,000
Accumulated Amortization	-750,000	'	-750,000	'	-606,000
Net	1,223,000	'	1,223,000	'	1,162,000
Total intangible assets	'	'	'	'	'
Accumulated Amortization	($750,000)	'	($750,000)	'	($606,000)

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill (Details 2) (USD $)	Apr. 30, 2014
Estimated annual amortization expense of intangible assets for next five years	'
Three month period ending July 31, 2014	$2,879,000
Fiscal 2015	11,032,000
Fiscal 2016	7,793,000
Fiscal 2017	7,217,000
Fiscal 2018	6,940,000
Fiscal 2019	$6,617,000

Intangible_Assets_and_Goodwill4

Intangible Assets and Goodwill (Details 3) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2012

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Jul. 31, 2012

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Endoscopy

Endoscopy

Water Purification and Filtration

Water Purification and Filtration

Healthcare Disposables

Healthcare Disposables

Dialysis

Dialysis

Dialysis

Other

Other

Specialty Packaging segment

Changes in Goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

$211,618,000

$183,655,000

$59,230,000

$59,230,000

$57,179,000

$53,288,000

$80,108,000

$55,864,000

$8,133,000

$8,133,000

$8,133,000

$6,968,000

$7,140,000

$6,532,000

Acquisitions

8,045,000

28,287,000

6,348,000

'

'

4,043,000

1,697,000

24,244,000

'

'

'

'

'

'

Foreign currency translation

-806,000

-324,000

'

'

-370,000

-152,000

'

'

'

'

'

-436,000

-172,000

'

Balance at the end of the period

$218,857,000

$211,618,000

$65,578,000

$59,230,000

$56,809,000

$57,179,000

$81,805,000

$80,108,000

$8,133,000

$8,133,000

$8,133,000

$6,532,000

$6,968,000

$6,532,000

Warranties_Details

Warranties (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Summary of activity in warranty reserves	'	'	'	'
Beginning balance	$1,201,000	$1,232,000	$1,261,000	$1,667,000
Provisions	583,000	479,000	1,820,000	1,182,000
Settlements	-567,000	-634,000	-1,863,000	-1,772,000
Foreign currency translation	'	'	-1,000	'
Ending Balance	$1,217,000	$1,077,000	$1,217,000	$1,077,000

Financing_Arrangements_Details

Financing Arrangements (Details) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

2 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Feb. 29, 2012

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Mar. 04, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Mar. 04, 2014

Apr. 30, 2014

Jan. 31, 2014

Jun. 09, 2014

Aug. 08, 2012

Aug. 08, 2012

Mar. 04, 2014

Jan. 31, 2014

Aug. 08, 2012

Aug. 08, 2012

Mar. 04, 2014

Mar. 04, 2014

Mar. 04, 2014

lender

Minimum

Minimum

Maximum

Maximum

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Term Loan Facility

Term Loan Facility

Term Loan Facility

Term Loan Facility

Borrowings of foreign currency

Letters of credit

Swing line loans

Minimum

Maximum

Lender's base rate

Lender's base rate

Lender's base rate

LIBOR

LIBOR

LIBOR

Subsequent Events

Interest rate swap with fixed interest cash flows

One month LIBOR

Interest rate swap with fixed interest cash flows

One month LIBOR

Minimum

Maximum

Minimum

Maximum

Cash flow hedge instruments

Interest rate swap with fixed interest cash flows

Cash flow hedge instruments

Interest rate swap with fixed interest cash flows

Cash flow hedge instruments

Cash flow hedge instruments

Financing Arrangements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

$250,000,000

'

'

'

'

'

'

'

'

'

$250,000,000

'

$100,000,000

'

'

'

'

'

'

'

$100,000,000

$30,000,000

$10,000,000

Borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

Term of line of credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Maximum additional borrowing capacity available at the entity's option

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs

'

'

'

'

'

'

'

1,318,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance costs

'

1,769,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

512,000

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance costs charged to interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

84,000

'

'

'

'

'

'

Margin on reference rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

1.25%

0.25%

1.25%

0.25%

1.25%

2.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

Reference rate, description

'

'

'

'One month LIBOR

'One month LIBOR

'Twelve month LIBOR

'Twelve month LIBOR

'

'

'

'

'lender's base rate

'

'

'LIBOR

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reference rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

3.50%

'

'

'

0.33%

0.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

Fees on unused portion of credit facilities (as a percent)

'

'

'

'

'

'

'

'

0.20%

0.20%

0.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of existing senior lenders of debt, whose variable interest cash flows will be exchanged by the entity with fixed interest cash flows

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowing initially hedged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

40,000,000

'

'

'

'

Reference rate, description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'one month LIBOR

'

'

'

'one month LIBOR

'

'

'

Interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

0.66%

'

'

'

Quarterly reduction in borrowings hedged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

Semi-annual reduction in borrowings hedged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

Shares of foreign subsidiaries pledged as security (as a percent)

'

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding borrowings

'

'

'

'

'

'

'

'

64,500,000

'

'

'

'

'

'

'

'

'

64,500,000

'

55,000,000

'

'

'

'

'

'

'

'

'

Repayment of borrowings

'

$5,000,000

$7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$9,500,000

'

'

'

'

'

'

'

'

'

Earnings_Per_Common_Share_Deta

Earnings Per Common Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Numerator for basic and diluted earnings per share:	'	'	'	'
Net income	$10,249,000	$8,998,000	$32,560,000	$29,026,000
Less income allocated to participating securities	-135,000	-137,000	-444,000	-454,000
Net income available to common shareholders	$10,114,000	$8,861,000	$32,116,000	$28,572,000
Denominator for basic and diluted earnings per share, as adjusted for participating securities:	'	'	'	'
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	40,813,778	40,365,939	40,716,018	40,201,691
Dilutive effect of stock options using the treasury stock method and the average market price for the period (in shares)	143,319	258,719	174,107	315,692
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,957,097	40,624,658	40,890,125	40,517,383
Basic earnings per share attributable to common stock (in dollars per share)	$0.25	$0.22	$0.79	$0.71
Diluted earnings per share attributable to common stock (in dollars per share)	$0.25	$0.22	$0.79	$0.71
Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive (in shares)	30,000	'	'	'

Earnings_Per_Common_Share_Deta1

Earnings Per Common Share (Details 2)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, to the entity's total weighted average number of shares and common stock equivalents, including participating securities	'	'	'	'
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,957,097	40,624,658	40,890,125	40,517,383
Participating securities (in shares)	544,752	626,415	566,545	646,104
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,501,849	41,251,073	41,456,670	41,163,487

Income_Taxes_Details

Income Taxes (Details)	9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	36.80%	35.40%
United States	'	'
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	37.40%	36.40%
Percentage of income before income taxes	97.00%	96.00%
Canada, Singapore and Netherlands	'	'
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	'	10.10%
Percentage of income before income taxes	'	4.00%
Canada, Singapore, Netherlands and Israel	'	'
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	27.60%	'
Percentage of income before income taxes	3.00%	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	9 Months Ended
	Apr. 30, 2014	Jul. 31, 2012
Reconciliation of the beginning and ending amounts of gross unrecognized tax benefits	'	'
Unrecognized tax benefits at the beginning of the period	$124,000	$124,000
Lapse of statute of limitations	-124,000	'
Unrecognized tax benefits at the end of the period	'	$124,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)

Apr. 30, 2014

Apr. 30, 2014

Nov. 05, 2013

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Jet Prep Ltd.

Jet Prep Ltd.

Compensation agreements

Contingent consideration

Contingent consideration

Assumed contingent obligation

Assumed contingent obligation

Deferred compensation and other

Expected interest payments under the credit facility

Credit Facility

Credit Facility

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Jet Prep Ltd.

Jet Prep Ltd.

Weighted average

Medivators B.V. subsidiary

Medivators B.V. subsidiary

Long term debt

'

'

'

'

'

'

'

'

'

'

'

'

Thereafter

'

'

'

'

'

'

'

'

'

'

$64,500,000

'

Total

'

'

'

'

'

'

'

'

'

'

64,500,000

'

Minimum commitments under noncancelable operating leases

'

'

'

'

'

'

'

'

'

'

'

'

Remaining fiscal year

1,011,000

'

'

'

'

'

'

'

'

'

'

'

2015

3,434,000

'

'

'

'

'

'

'

'

'

'

'

2016

2,442,000

'

'

'

'

'

'

'

'

'

'

'

2017

1,757,000

'

'

'

'

'

'

'

'

'

'

'

2018

1,360,000

'

'

'

'

'

'

'

'

'

'

'

Thereafter

3,760,000

'

'

'

'

'

'

'

'

'

'

'

Total

13,764,000

'

'

'

'

'

'

'

'

'

'

'

Other commitments

'

'

'

'

'

'

'

'

'

'

'

'

Remaining fiscal year

'

'

'

1,192,000

'

'

'

'

14,000

'

'

'

2015

'

'

'

6,074,000

177,000

'

143,000

'

58,000

'

'

'

2016

'

'

'

1,496,000

629,000

'

318,000

'

43,000

'

'

'

2017

'

'

'

600,000

1,120,000

'

549,000

'

41,000

'

'

'

2018

'

'

'

350,000

1,609,000

'

711,000

'

36,000

'

'

'

Thereafter

'

'

'

846,000

4,465,000

'

465,000

'

27,000

'

'

'

Total

'

'

'

10,558,000

8,000,000

'

2,186,000

'

219,000

'

'

'

Total contractual obligations

'

'

'

'

'

'

'

'

'

'

'

'

Remaining fiscal year

2,522,000

'

'

'

'

'

'

'

'

305,000

'

'

2015

11,105,000

'

'

'

'

'

'

'

'

1,219,000

'

'

2016

6,147,000

'

'

'

'

'

'

'

'

1,219,000

'

'

2017

5,286,000

'

'

'

'

'

'

'

'

1,219,000

'

'

2018

5,285,000

'

'

'

'

'

'

'

'

1,219,000

'

'

Thereafter

74,774,000

'

'

'

'

'

'

'

'

711,000

'

'

Total

105,119,000

'

'

'

'

'

'

'

'

5,892,000

'

'

Interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

1.89%

Contingent consideration

'

5,026,000

4,760,000

'

'

5,026,000

'

'

'

'

'

'

Assumed contingent obligation

'

$1,045,000

'

'

'

'

'

$1,045,000

'

'

'

'

Discount rate of potential payments (as a percent)

'

'

'

'

'

11.50%

'

11.50%

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies (Details 2) (Jet Prep Ltd., Medivators B.V. subsidiary, USD $)	0 Months Ended
	Nov. 05, 2013	Apr. 30, 2014
Jet Prep Ltd. | Medivators B.V. subsidiary	'	'
Long-Term Contractual Obligations	'	'
Contingent consideration liability	$4,760,000	$5,026,000
Assumed contingent obligation	'	$1,045,000
Period over which potential cash contingent consideration is payable	'7 years	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Components and changes in accumulated other comprehensive income (loss)	'	'	'	'
Balance at the beginning of the period	$9,406,000	$8,395,000	$10,977,000	$8,175,000
Other comprehensive income (loss) before reclassifications	163,000	-303,000	-1,558,000	-106,000
Income tax effect on other comprehensive loss before reclassification	'	73,000	17,000	22,000
Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	'	53,000	96,000	168,000
Reclassification adjustments for ineffective hedge on interest rate swap included in net income during the period	'	'	113,000	'
Income tax effect on reclassification adjustments	'	-22,000	-76,000	-63,000
Balance at the end of the period	9,569,000	8,196,000	9,569,000	8,196,000
Foreign Currency Translation Adjustments	'	'	'	'
Components and changes in accumulated other comprehensive income (loss)	'	'	'	'
Balance at the beginning of the period	9,406,000	8,540,000	11,080,000	8,385,000
Other comprehensive income (loss) before reclassifications	163,000	-243,000	-1,511,000	-32,000
Income tax effect on other comprehensive loss before reclassification	'	51,000	'	-5,000
Balance at the end of the period	9,569,000	8,348,000	9,569,000	8,348,000
Interest Rate Swap Agreements	'	'	'	'
Components and changes in accumulated other comprehensive income (loss)	'	'	'	'
Balance at the beginning of the period	'	-145,000	-103,000	-210,000
Other comprehensive income (loss) before reclassifications	'	-60,000	-47,000	-74,000
Income tax effect on other comprehensive loss before reclassification	'	22,000	17,000	27,000
Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	'	53,000	96,000	168,000
Reclassification adjustments for ineffective hedge on interest rate swap included in net income during the period	'	'	113,000	'
Income tax effect on reclassification adjustments	'	-22,000	-76,000	-63,000
Balance at the end of the period	'	($152,000)	'	($152,000)

Operating_Segments_Details

Operating Segments (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Concentration risk	'	'	'	'
Consolidated net sales	$120,058,000	$105,009,000	$357,372,000	$311,053,000
Water Purification and Filtration	'	'	'	'
Concentration risk	'	'	'	'
Consolidated net sales	38,281,000	32,943,000	118,750,000	98,473,000
Dialysis	'	'	'	'
Concentration risk	'	'	'	'
Consolidated net sales	7,349,000	8,072,000	22,269,000	25,019,000
Healthcare Disposables	'	'	'	'
Concentration risk	'	'	'	'
Consolidated net sales	25,506,000	22,674,000	76,471,000	66,968,000
Segment sales | Customer concentration | Water Purification and Filtration | DaVita	'	'	'	'
Concentration risk	'	'	'	'
Concentration risk (as a percent)	'	'	24.90%	'
Segment sales | Customer concentration | Water Purification and Filtration | Another large customer	'	'	'	'
Concentration risk	'	'	'	'
Concentration risk (as a percent)	'	'	22.10%	'
Segment sales | Customer concentration | Dialysis | DaVita	'	'	'	'
Concentration risk	'	'	'	'
Concentration risk (as a percent)	'	'	36.10%	'
Segment sales | Customer concentration | Healthcare Disposables | Four customers	'	'	'	'
Concentration risk	'	'	'	'
Number of customers concentration risk	'	'	4	'
Concentration risk (as a percent)	'	'	51.90%	'
Net sales | Customer concentration | DaVita	'	'	'	'
Concentration risk	'	'	'	'
Concentration risk (as a percent)	'	'	10.50%	10.50%
Consolidated net sales	'	'	$37,595,000	$32,785,000
Net sales | Customer concentration | DaVita and another large customer	'	'	'	'
Concentration risk	'	'	'	'
Number of customers concentration risk	'	'	2	'
Concentration risk (as a percent)	'	'	17.90%	'
Net sales | Customer concentration | Four customers	'	'	'	'
Concentration risk	'	'	'	'
Number of customers concentration risk	'	'	4	'
Concentration risk (as a percent)	'	'	11.10%	'

Operating_Segments_Details_2

Operating Segments (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Information as to operating segments	'	'	'	'
Net sales	$120,058,000	$105,009,000	$357,372,000	$311,053,000
Operating income	16,826,000	14,223,000	53,347,000	47,058,000
Interest expense, net	-535,000	-733,000	-1,809,000	-2,141,000
Income before income taxes	16,291,000	13,490,000	51,538,000	44,917,000
Operating Segments	'	'	'	'
Information as to operating segments	'	'	'	'
Operating income	20,870,000	17,177,000	64,715,000	56,294,000
General corporate expenses	'	'	'	'
Information as to operating segments	'	'	'	'
Operating income	-4,044,000	-2,954,000	-11,368,000	-9,236,000
Endoscopy	'	'	'	'
Information as to operating segments	'	'	'	'
Net sales	47,260,000	39,694,000	135,460,000	115,795,000
Operating income	8,482,000	7,241,000	24,884,000	24,386,000
Water Purification and Filtration	'	'	'	'
Information as to operating segments	'	'	'	'
Net sales	38,281,000	32,943,000	118,750,000	98,473,000
Operating income	6,292,000	3,649,000	19,457,000	11,995,000
Healthcare Disposables	'	'	'	'
Information as to operating segments	'	'	'	'
Net sales	25,506,000	22,674,000	76,471,000	66,968,000
Operating income	4,262,000	3,991,000	14,544,000	12,791,000
Dialysis	'	'	'	'
Information as to operating segments	'	'	'	'
Net sales	7,349,000	8,072,000	22,269,000	25,019,000
Operating income	1,515,000	1,990,000	5,275,000	6,478,000
Other	'	'	'	'
Information as to operating segments	'	'	'	'
Net sales	1,662,000	1,626,000	4,422,000	4,798,000
Operating income	$319,000	$306,000	$555,000	$644,000